<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67250</article-id><article-id pub-id-type="doi">10.7554/eLife.67250</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Cardiac pathologies in mouse loss of imprinting models are due to misexpression of H19 long noncoding RNA</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-227694"><name><surname>Park</surname><given-names>Ki-Sun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1322-767X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="pa1">‡</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-227695"><name><surname>Rahat</surname><given-names>Beenish</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0371-2356</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-244943"><name><surname>Lee</surname><given-names>Hyung Chul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-131002"><name><surname>Yu</surname><given-names>Zu-Xi</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227696"><name><surname>Noeker</surname><given-names>Jacob</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4344-3114</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-177058"><name><surname>Mitra</surname><given-names>Apratim</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244944"><name><surname>Kean</surname><given-names>Connor M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227697"><name><surname>Knutsen</surname><given-names>Russell H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6761-6502</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-107357"><name><surname>Springer</surname><given-names>Danielle</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6261-9744</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-244945"><name><surname>Gebert</surname><given-names>Claudia M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1282-1602</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227699"><name><surname>Kozel</surname><given-names>Beth A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9757-7118</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-225347"><name><surname>Pfeifer</surname><given-names>Karl</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0254-682X</contrib-id><email>pfeiferk@mail.nih.gov</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Pathology Core, National Heart Lung and Blood Institute, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Laboratory of Vascular and Matrix Genetics, National Heart Lung and Blood Institute, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Murine Phenotyping Core, National Heart Lung and Blood Institute, National Institutes of Health</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Prosser</surname><given-names>Benjamin L</given-names></name><role>Reviewing Editor</role><aff><institution>University of Pennsylvania Perelman School of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Morrisey</surname><given-names>Edward E</given-names></name><role>Senior Editor</role><aff><institution>University of Pennsylvania</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn><fn fn-type="present-address" id="pa1"><label>‡</label><p>Division of Clinical Medicine, Korea Institute of Oriental Medicine, Daejeon, South Korea</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>17</day><month>08</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67250</elocation-id><history><date date-type="received" iso-8601-date="2021-02-05"><day>05</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-08-04"><day>04</day><month>08</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-02-23"><day>23</day><month>02</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.02.23.432554"/></event></pub-history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67250-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-67250-figures-v2.pdf"/><abstract><p>Maternal loss of imprinting (LOI) at the <italic>H19/IGF2</italic> locus results in biallelic <italic>IGF2</italic> and reduced <italic>H19</italic> expression and is associated with Beckwith–-Wiedemann syndrome (BWS). We use mouse models for LOI to understand the relative importance of <italic>Igf2</italic> and <italic>H19</italic> mis-expression in BWS phenotypes. Here we focus on cardiovascular phenotypes and show that neonatal cardiomegaly is exclusively dependent on increased <italic>Igf2</italic>. Circulating IGF2 binds cardiomyocyte receptors to hyperactivate mTOR signaling, resulting in cellular hyperplasia and hypertrophy. These <italic>Igf2</italic>-dependent phenotypes are transient: cardiac size returns to normal once <italic>Igf2</italic> expression is suppressed postnatally. However, reduced <italic>H19</italic> expression is sufficient to cause progressive heart pathologies including fibrosis and reduced ventricular function. In the heart, <italic>H19</italic> expression is primarily in endothelial cells (ECs) and regulates EC differentiation both in vivo and in vitro. Finally, we establish novel mouse models to show that cardiac phenotypes depend on <italic>H19</italic> lncRNA interactions with <italic>Mirlet7</italic> microRNAs.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>genomic imprinting</kwd><kwd>H19 lncRNA</kwd><kwd>IGF2</kwd><kwd>beckwith wiedemann syndrome</kwd><kwd>epigenetics</kwd><kwd>heart</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009633</institution-id><institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution></institution-wrap></funding-source><award-id>ZIAHD001804</award-id><principal-award-recipient><name><surname>Pfeifer</surname><given-names>Karl</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>ZIA HL006247</award-id><principal-award-recipient><name><surname>Kozel</surname><given-names>Beth A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Maternal loss of imprinting at the <italic>Igf2/H19</italic> locus reduces expression of <italic>H19</italic> lncRNA and thereby leads to progressive cardiac pathologies in a mouse Beckwith–Wiedemann syndrome model.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>There are 100–200 imprinted genes in mammals. These genes are organized into discrete clusters where monoallelic expression is dependent on a shared regulatory element known as the <italic>Imprinting Control Region</italic> (<italic>ICR</italic>) (<xref ref-type="bibr" rid="bib3">Barlow and Bartolomei, 2014</xref>). Imprinted genes are frequently involved in human disease and developmental disorders (<xref ref-type="bibr" rid="bib16">Eggermann et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Feinberg and Tycko, 2004</xref>; <xref ref-type="bibr" rid="bib32">Horsthemke, 2014</xref>; <xref ref-type="bibr" rid="bib39">Kalish et al., 2014</xref>; <xref ref-type="bibr" rid="bib65">Peters, 2014</xref>). Sometimes, these diseases are due to inactivating point mutations of the only transcriptionally active allele. Alternatively, imprinting diseases are caused by disruption of ICR function, leading to mis-expression of all genes in the cluster.</p><p>One imprinted cluster is the <italic>IGF2/H19</italic> locus on human chromosome 11p15.5. Imprinting in this &gt;100 kb region is determined by the <italic>H19ICR</italic>, located just upstream of the <italic>H19</italic> promoter (<xref ref-type="bibr" rid="bib37">Kaffer et al., 2000</xref>; <xref ref-type="bibr" rid="bib77">Thorvaldsen et al., 1998</xref>). As described in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, the <italic>H19ICR</italic> organizes the locus such that transcription of the <italic>IGF2</italic> (<italic><underline>I</underline>nsulin-<underline>l</underline>ike <underline>G</underline>rowth <underline>F</underline>actor <underline>2</underline></italic>) and <italic>H19</italic> genes are restricted to the paternal and maternal chromosomes, respectively (<xref ref-type="bibr" rid="bib33">Ideraabdullah et al., 2008</xref>; <xref ref-type="bibr" rid="bib60">Murrell, 2011</xref>; <xref ref-type="bibr" rid="bib87">Yoon et al., 2007</xref>). (Note that in medical genetics, the <italic>H19ICR</italic> is also known as Imprinting Center one or IC1).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>The H19/Igf2</italic> locus.</title><p>(<bold>A</bold>) Schematic of maternal (mat) and paternal (pat) chromosomes in wild-type and in loss of imprinting (LOI) mice. Gene expression is indicated by horizontal arrows. In wild-type mice, the paternal copy of the imprinting control region (ICR) is inactivated by DNA methylation (filled lollipops). In LOI patients, inappropriate inactivation of the maternal ICR typically occurs due to microdeletion or to inappropriate DNA methylation. In the mouse LOI model, the maternal ICR is inactivated by deletion. (<bold>B</bold>) Schematic of <italic>wild-type</italic>, <italic>ΔEx1</italic>, and <italic>ΔLet7 H19</italic> alleles. <italic>H19</italic> exons 1–5 are shown as filled rectangles. <italic>ΔEx1</italic> is a 700 bp deletion at the 5’ end of exon 1. <italic>ΔLet7</italic> was constructed for this study by simultaneous deletion of <italic>Mirlet7</italic> binding sites in <italic>H19</italic> exons 1 and 4. The blue oval identifies coding sequences for <italic>Mir675-3p</italic> and <italic>-5</italic> p. Arrowheads show the direction of transcription. (<bold>C–E</bold>). Maternal loss of imprinting results in reduced <italic>H19</italic> lncRNA and 2× doses of <italic>Igf2</italic>. (<bold>C, D</bold>) Hearts were isolated from wild type (WT) or from <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic> (LOI) littermates at postnatal day 2 or at 2 months. RNAs were extracted, analyzed by qRT-PCR, normalized to GAPDH, and then normalized to levels observed in wild-type neonates. Despite the dramatic postnatal repression, <italic>H19</italic> expression in adults remains substantial as <italic>H19</italic> lncRNA is in the top 10-percentile of all RNAs. (<bold>C</bold>) IGF2 peptide levels in serum were measured by ELISA. Statistical significance was evaluated with Student’s t-test type 2.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Maternal Loss of Imprinting (LOI) results in decreased Igf2 and increased H19 expression.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig1-v2.tif"/></fig><p><italic>IGF2</italic> encodes a peptide hormone that binds to and activates the insulin receptor (InsR) and insulin-like growth factor one receptor (Igf1R) kinases to promote cell growth and proliferation in many cell types including cardiomyocytes (<xref ref-type="bibr" rid="bib4">Bergman et al., 2013</xref>; <xref ref-type="bibr" rid="bib23">Geng et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bib83">Wang et al., 2019</xref>). In contrast, the functional product of the <italic>H19</italic> gene is a 2.3 kb long non-coding RNA whose biochemical functions remain controversial (<xref ref-type="bibr" rid="bib6">Brannan et al., 1990</xref>; <xref ref-type="bibr" rid="bib21">Gabory et al., 2010</xref>). Reported roles for the <italic>H19</italic> lncRNA include (1) acting as the precursor for microRNAs (<italic>Mir675-3p</italic> and <italic>Mir675-5p</italic>) (<xref ref-type="bibr" rid="bib7">Cai and Cullen, 2007</xref>; <xref ref-type="bibr" rid="bib41">Keniry et al., 2012</xref>), (2) regulating the bioavailability of <italic>Mirlet7 (let-7</italic>) microRNAs (<xref ref-type="bibr" rid="bib22">Gao et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Geng et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Kallen et al., 2013</xref>; <xref ref-type="bibr" rid="bib49">Li et al., 2015</xref>), (3) interacting with p53 protein to reduce its function (<xref ref-type="bibr" rid="bib28">Hadji et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Park et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Peng et al., 2017</xref>; <xref ref-type="bibr" rid="bib86">Yang et al., 2012</xref>; <xref ref-type="bibr" rid="bib91">Zhang et al., 2019</xref>; <xref ref-type="bibr" rid="bib89">Zhang et al., 2017</xref>), and (4) regulating DNA methylation to thereby modulate gene expression (<xref ref-type="bibr" rid="bib93">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Zhou et al., 2015</xref>).</p><p>In humans, disruption of the maternally inherited <italic>H19ICR</italic> results in biallelic <italic>IGF2</italic> along with reduced <italic>H19</italic> expression and is associated with the developmental disorder, Beckwith–Wiedemann syndrome (BWS) (<xref ref-type="bibr" rid="bib34">Jacob et al., 2013</xref>). BWS is a fetal overgrowth disorder but the specific manifestations of overgrowth vary between patients. Cardiomegaly is a common newborn presentation but typically resolves without treatment. Cardiomyopathies are rarer and include ventricular dilation, valve/septal defects, fibrotic and rhabdomyoma tumors, and vascular abnormalities (<xref ref-type="bibr" rid="bib9">Cohen, 2005</xref>; <xref ref-type="bibr" rid="bib11">Descartes et al., 2008</xref>; <xref ref-type="bibr" rid="bib15">Drut et al., 2006</xref>; <xref ref-type="bibr" rid="bib18">Elliott et al., 1994</xref>; <xref ref-type="bibr" rid="bib27">Greenwood et al., 1977</xref>; <xref ref-type="bibr" rid="bib44">Knopp et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Longardt et al., 2014</xref>; <xref ref-type="bibr" rid="bib68">Ryan et al., 1989</xref>; <xref ref-type="bibr" rid="bib69">Satgé et al., 2005</xref>). BWS incidence correlates with artificial reproductive technologies (ART) (<xref ref-type="bibr" rid="bib10">DeBaun et al., 2003</xref>; <xref ref-type="bibr" rid="bib25">Gicquel et al., 2003</xref>; <xref ref-type="bibr" rid="bib29">Halliday et al., 2004</xref>; <xref ref-type="bibr" rid="bib30">Hattori et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Johnson et al., 2018</xref>; <xref ref-type="bibr" rid="bib54">Maher et al., 2003</xref>; <xref ref-type="bibr" rid="bib61">Mussa et al., 2017</xref>), and among BWS patients, the frequency of heart defects is higher in those born via ART (<xref ref-type="bibr" rid="bib76">Tenorio et al., 2016</xref>).</p><p>We have generated a mouse model that recapitulates the molecular loss of imprinting (LOI) phenotypes of BWS (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib73">Srivastava et al., 2000</xref>). That is, deletion of the <italic>H19ICR</italic> on the maternal chromosome results in biallelic <italic>Igf2</italic> and reduced levels of <italic>H19</italic>. In this study, we show that the LOI mouse model displays cardiovascular defects seen in BWS patients. Genetic and developmental analyses indicate that mis-expression of <italic>Igf2</italic> and <italic>H19</italic> act independently on distinct cell types to cause the cardiac phenotypes. During fetal development, increased circulating IGF2 activates AKT/mTOR pathways in cardiomyocytes resulting in cellular hypertrophy and hyperplasia. This neonatal hypertrophy is transient, non-pathologic, and unaffected by the presence or absence of a functional <italic>H19</italic> gene. However, loss of <italic>H19</italic> lncRNA results in cardiac fibrosis and hypertrophy and a progressive cardiac pathology in adult animals. In both neonatal and adult hearts, <italic>H19</italic> lncRNA expression is restricted to endothelial cells (ECs). In vivo, loss of <italic>H19</italic> results in high incidence of ECs that co-express endothelial and mesenchymal markers. Similarly, primary cardiac endothelial cells can be driven toward a mesenchymal phenotype by manipulating <italic>H19</italic> expression levels. Thus, this research identifies a novel developmental role for the <italic>H19</italic> lncRNA in regulating cardiac endothelial cells. In fact, this role for <italic>H19</italic> in restricting endothelial cell transitions in the heart is unexpected given previous analyses of <italic>H19</italic> function in vitro in transformed cell lines. Finally, we describe structure–function analyses in two novel mouse models (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) and show that <italic>H19</italic> lncRNA acts by regulating <italic>Mirlet7</italic> bioavailability.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Defective structure and function in hearts from mice with H19/Igf2 maternal LOI</title><p>Wild-type and LOI mice were generated by crossing <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic> with wild-type C57Bl/6 J males. (See <xref ref-type="fig" rid="fig1">Figure 1A</xref> for a description of the <italic>H19ΔICR</italic> allele). In mice (as in humans), maternal LOI results in biallelic (2×) expression of <italic>Igf2</italic> and reduced levels of <italic>H19</italic> RNA (<xref ref-type="fig" rid="fig1">Figure 1C–E</xref>). Hearts isolated from P1 LOI mice display cellular hyperplasia and cellular hypertrophy. Hyperplasia is indicated by increased staining for Ki-67 (a marker for cell proliferation) in tissue sections (<xref ref-type="fig" rid="fig2">Figure 2A,C</xref>) and by increased levels of Ki-67 and of cyclins E1 and D1 in protein extracts (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Cellular hypertrophy is demonstrated by measuring surface areas of primary cardiomyocytes isolated from wild-type and LOI neonates (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref>). Apart from their increased size, neonatal LOI hearts do not display any obvious pathologies. For example, we did not see increased fibrosis or expression of protein markers associated with heart disease. Furthermore, by 2 months of age, we were unable to distinguish LOI mice by cardiomegaly as measured by heart weight/tibia length ratios: WT = 6.7 ± 0.3 mg/mm (N = 8), LOI = 6.8 ± 0.3 mg/mm (N = 13), p=0.79 (Student’s t-test).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Cardiac hypertrophy in neonatal LOI mice is mediated by circulating IGF2 activation of AKT/mTOR signaling in cardiomyocytes and is independent of <italic>H19</italic> gene function.</title><p>(<bold>A, B</bold>) Heart morphology in wild-type, LOI, and LOI+ H19 BAC littermates (<bold>A</bold>) or in wild-type and <italic>H19</italic>-deficient littermates (<bold>B</bold>) Top panels, transverse sections were taken from fixed hearts at 200 mm from the apex. Bottom panels, Ki-67 (brown stain) is a marker for cell proliferation. LOI, <italic>H19<sup>ΔICR</sup> /H19<sup>+</sup></italic>; LOI+ BAC, <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic> that also carry a 140 kb Bacterial Artificial Chromosome transgene that restores normal <italic>H19</italic> expression (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Notice the thickened walls, misshaped right ventricles, and high levels of Ki-67 expression in LOI and in LOI+ BAC transgenic neonates. (<bold>C</bold>) Quantitation of Ki-67 expression as assayed in panel A. (N = 5). (<bold>D</bold>) Immunoblot analyses of heart extracts prepared from wild-type and LOI littermates. LOI hearts show increased levels of proliferation markers, Ki-67, Cyclin EI, and Cyclin D1 and also increased levels of phosphorylated AKT and S6K1 (a target of mTORC1). See <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref> for quantifed results. (<bold>E, F</bold>) Cardiomyocyte cellular hypertrophy in LOI animals is cell non-autonomous. Primary cardiomyocyte cultures were prepared from wild type, LOI, and from littermates carrying an <italic>ICR</italic> deletion only in cardiomyocytes (see below). Cells were cultured overnight, stained for MYH6 (to identify cardiomyocytes) and Phalloidin (to facilitate measurement of surface areas). For each culture (N = 5 per genotype), at least 30 cells were measured. (<bold>G, H</bold>) Exogenous IGF2 peptide induces cellular hypertrophy in wild-type cardiomyocytes through mTOR pathways. Primary cardiomyocytes were prepared from wild-type neonates and cultured overnight with IGF2 before measurement of cell surface area (<bold>G</bold>) or preparation of protein extracts for immunoblotting. (<bold>H</bold>) The effect of increased IGF2 is prevented by treatment with BMS 754807 or with Rapamycin. BMS inhibits IgfR1 and Ins2 receptor kinases (<xref ref-type="bibr" rid="bib8">Carboni et al., 2009</xref>). Rapamcyin blocks a subset of mTOR activities (<xref ref-type="bibr" rid="bib48">Li et al., 2014</xref>). See <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref> for quantified results. (<bold>I, J</bold>) LOI phenotypes in cardiomyocytes are cell non-autonomous. <italic>H19<sup>ICRflox</sup>/H19<sup>ΔICR</sup></italic> females were crossed with males carrying the <italic>Myh6-Cre</italic> transgene to generate four kinds of pups: <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic> (#1) and <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup> Myh6</italic> Cre (#3) will display LOI in all cell types; <italic>H19<sup>ICRflox</sup>/H19<sup>+</sup></italic> (#2) will display wild-type expression patterns for <italic>Igf2</italic> and <italic>H19</italic>; and <italic>H19<sup>ICRflox</sup>/H19<sup>+</sup> Myh6</italic> Cre mice will show LOI only in cardiomyocytes. Hearts were analyzed for cellular hypertrophy (<bold>E</bold>), megacardia and hyperplasia (<bold>I</bold>), and protein expression (<bold>J</bold>). See <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref> for quantified results of protein expression. In all assays, <italic>H19<sup>ICRflox</sup>/H19<sup>+</sup> Myh6</italic> Cre mice were highly similar to their wild-type littermates and distinct from the congenital LOI littermates. *p&lt;0.05; ***p&lt;0.001 (Student’s t-test). LOI, loss of imprinting (<italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic>).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Analyses of LOI phenotype in neonatal mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title><italic>LOI-dependent changes in protein expression in neonatal mice – quantitated western blots</italic>.</title><p>(<bold>A</bold>) Hyperactivation of AKT/mTOR signaling in LOI neonatal hearts. See <xref ref-type="fig" rid="fig2">Figure 2D</xref> for representative blot. For each sample, gel loading was based on total protein concentration. Counts were first normalized to GAPDH and then these values were normalized to the average GAPDH to combine results from two gels. Biological replicates = 4. (<bold>B</bold>) Hyperactivation of AKT/mTOR in primary cardiomyocytes. See <xref ref-type="fig" rid="fig2">Figure 2H</xref> for representative blot. For each sample, counts were normalized to control lanes (no drug treatment). Biological replicates = 4. (<bold>C</bold>) LOI hypertrophy in neonatal LOI mice is cell non-autonomous. See <xref ref-type="fig" rid="fig2">Figure 2J</xref> for representative blot. Samples from littermates were run on separate gels: counts were normalized to GAPDH and then fold-changes relative to WT (<italic>H19<sup>flox</sup>/H19<sup>+</sup></italic> with no Cre) were calculated. Results from three gels (three independent litters) are displayed. Statistical significance was evaluated by Student’s t-test type 2. For each panel, quantitation was by NIH Image J.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>The H19 BAC transgene restores H19 expression in LOI hearts.</title><p>Hearts were isolated from LOI or from LOI+ <italic>H19</italic> BAC transgenic littermates at postnatal day 2 and at 2 months. RNAs were extracted, analyzed by qRT-PCR, normalized to <italic>GAPDH,</italic> and then normalized to levels observed in LOI+ BAC animals. LOI+ BAC mice display <italic>H19</italic> expression levels that are not distinguishable from wild-type animals of equivalent age.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>The H19ΔEx1 deletion reduces H19 lncRNA but has only only a small impact on Mir675-3p and -5p accumulation.</title><p>RNAs were extracted from whole hearts isolated from wild type and from <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> + at e17.5 and at 1 year of age. <italic>H19</italic> lncRNA levels were normalized to <italic>GAPDH. Mir675</italic> levels were normalized to <italic>U6</italic> microRNA. In each experiment, expression in <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> is normalized to the wild-type littermates. Statistical significance was evaluated with Student’s t-test type 2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title><italic>Tissue-specific expression of H19</italic>.</title><p>Tissues were isolated from wild-type littermates at postnatal day 2. RNAs were extracted, analyzed by qRT-PCR, normalized to <italic>GAPDH,</italic> and then normalized to levels observed in skeletal muscle. Statistical significance was evaluated with Student’s t-test type 2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig2-figsupp4-v2.tif"/></fig></fig-group><p>We continued to monitor cardiovascular phenotypes in LOI and wild-type mice until 19 months of age. By 6 months, LOI mice displayed cardiac hypertrophy as measured by a 28% increase in heart weight/tibia length ratios (wild type = 10.0 ± 1.7 mg/mm, N = 8; LOI = 12.8 ± 0.2 mg/mm, N = 10; p=0.005). Transverse sections revealed increased fiber diameter in LOI hearts (wild type = 10.2 ± 0.7 μm; LOI = 14.4 ± 0.8 μm; p=0.007) (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Cardiac hypertrophy is often a poor prognostic sign and is associated with most forms of heart failure (<xref ref-type="bibr" rid="bib31">Heinzel et al., 2015</xref>; <xref ref-type="bibr" rid="bib78">Vakili et al., 2001</xref>). However, hypertrophy can also be physiologic (<xref ref-type="bibr" rid="bib58">McMullen and Jennings, 2007</xref>; <xref ref-type="bibr" rid="bib72">Shimizu and Minamino, 2016</xref>). The hypertrophy in LOI mice might be considered pathologic based on increased levels of ANP, Myh7, cleaved Caspase-3, cleaved Caspase-7, and cleaved PARP proteins as well as decreased levels of Serca2 protein in all LOI mice by 1 year of age (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib59">Mitra et al., 2013</xref>; <xref ref-type="bibr" rid="bib79">van Empel et al., 2005</xref>). Finally, both interstitial and perivascular fibrosis are prominent in LOI animals by 6 months of age (<xref ref-type="fig" rid="fig3">Figure 3C,D</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Cardiomyopathies in adult LOI mice.</title><p>(<bold>A</bold>) Transverse sections were collected midway along the longitudinal axis from hearts collected from 6-month-old wild-type (WT) and LOI mice and stained with hematoxylin and eosin. (<bold>B</bold>) Immunoblot analyses of whole heart extracts prepared from 1 year WT and LOI mice. Note the altered expression of ANP (Atrial Natriuretic Peptide), Myh7 (Myosin Heavy Chain 7), Serca2 (Sarco/endoplasmic reticulum Ca<sup>++</sup> ATPase), Cleaved Caspase-3, and Cleaved Poly ADP Ribose Polymerase (PARP). β-Tubulin is a loading control. See <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref> for quantified data. (<bold>C, D</bold>) Masson’s trichrome staining of sections described in (<bold>A</bold>). Red, muscle fibers; blue, collagen. Sections from five wild-type and five LOI animals were used to calculate fibrosis. Statistical significance was evaluated with Student’s t-test type 2. (<bold>E, F</bold>) Ascending aortas were isolated from 10 wild-type and 8 LOI mice at age 20 months and pressure-diameter curves generated. (<bold>E</bold>) Increased diameters across a wide range of applied pressures. (<bold>F</bold>) Increased segmental distensibility across physiologically relevant pressures. Data were analyzed by two-way repeated measure ANOVA. Analyses of carotid arteris are described in <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Analyses of cardiomyopathies in adult LOI mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>LOI-dependent changes in protein expression in adult mice – quantitated western blots.</title><p>Expression of heart failure biomarkers in adult LOI hearts. See <xref ref-type="fig" rid="fig3">Figure 3D</xref> for blot. Biological replicates = 3. Statistical significance was evaluated by Student’s t-test type 2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Echocardiography measures from 11 wild-type and 10 LOI mice at 13 months and for 11 wild-type and 9 LOI mice at 16 months.</title><p>Loss of imprinting results in ventricular and vascular phenotypes that vary from mouse to mouse. (<bold>A–C</bold>). Left ventricular phenotypes are progressive and stratify with time. (<bold>D–F</bold>). Arterial defects, including abnormal outflow and increased artery diameters, do not progress. Arterial diameter phenotypes are already stratified at 13 months. Statistical significance was evaluated with Student’s t-test type 1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Decreased systolic and pulse pressures in LOI mice.</title><p>Blood pressures from 10 wild-type and 8 LOI sedated mice were measured as described in Materials and methods. Means and standard deviation are shown as whiskers underlying the data points. Systolic and diastolic blood pressure data were analyzed by Tukey’s test; pulse pressure data were analyzed using one-way ANOVA. **p&lt;0.01; ****p&lt;0.0001. Diastolic pressures were not significantly different.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig3-figsupp3-v2.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Increased vessel diameter and distensibility in carotid arteries isolated from 10 wild-type and 8 LOI mice at 16 months.</title><p>(<bold>A</bold>) Increased diameters across a wide range of applied pressures. (<bold>B</bold>) Increased segmental distensibility across physiologically relevant pressures. (<bold>A</bold>, <bold>B</bold>) **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001 (two-way repeated measure ANOVA).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig3-figsupp4-v2.tif"/></fig></fig-group><p><xref ref-type="table" rid="table1">Table 1</xref> summarizes echocardiography phenotypes from 13-month-old mice. Left ventricles (LV) from LOI mice are dilated (as measured by increased LV volumes at both systole and diastole), mildly hypertrophic (as measured by increased wall thickness, LVAW diastole and LVPW diastole), and show diminished function (as measured by reduced ejection fractions, % EF). LOI mice showed large increases in velocity and turbulence of blood flow from the LV outflow tract. Finally, major vessel lumen diameters (measured at the aortic arch and the first brachial arch) were &gt;30% larger in LOI mice.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Echocardiograph of wild-type (WT) and loss of imprinting (LOI) mice at 13 and at 16 months.</title><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Analyses of heart function in wild type and LOI adult mice.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-table1-data1-v2.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" valign="bottom">Phenotype</th><th align="left" colspan="4" valign="bottom">13 months</th><th align="left" colspan="4" valign="bottom">16 months</th></tr><tr><th align="left" colspan="2" valign="bottom">Mean ± SEM</th><th align="left" rowspan="2" valign="bottom">p-value</th><th align="left" rowspan="2" valign="bottom">% Change</th><th align="left" colspan="2" valign="bottom">Mean ± SEM</th><th align="left" rowspan="2" valign="bottom">p-value</th><th align="left" rowspan="2" valign="bottom">% Change</th></tr><tr><th align="left" valign="bottom">Wt (N = 11)</th><th align="left" valign="bottom">Loi (N = 10)</th><th align="left" valign="bottom">Wt (N = 11)</th><th align="left" valign="bottom">Loi (N = 9)</th></tr></thead><tbody><tr><td align="left" valign="bottom">Heart rate (bpm)</td><td align="char" char="plusmn" valign="bottom">504 ± 12</td><td align="char" char="plusmn" valign="bottom">499 ± 11</td><td align="char" char="." valign="bottom">0.77</td><td align="char" char="." valign="bottom">-1</td><td align="char" char="plusmn" valign="bottom">529 ± 20</td><td align="char" char="plusmn" valign="bottom">540 ± 16</td><td align="char" char="." valign="bottom">0.77</td><td align="char" char="." valign="bottom">2</td></tr><tr><td align="left" valign="bottom">LV volume systole (μl)</td><td align="char" char="plusmn" valign="bottom">24.1 ± 1.5</td><td align="char" char="plusmn" valign="bottom">39.2 ± 4.7</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">63</td><td align="char" char="plusmn" valign="bottom">28.3 ± 1.4</td><td align="char" char="plusmn" valign="bottom">46.6 ± 1.6</td><td align="char" char="." valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">65</td></tr><tr><td align="left" valign="bottom">LV volume diastole (μl)</td><td align="char" char="plusmn" valign="bottom">67.9 ± 3.0</td><td align="char" char="plusmn" valign="bottom">79.8 ± 4.6</td><td align="char" char="." valign="bottom">0.05</td><td align="char" char="." valign="bottom">17</td><td align="char" char="plusmn" valign="bottom">74.2 ± 2.8</td><td align="char" char="plusmn" valign="bottom">91.3 ± 3.3</td><td align="char" char="." valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">23</td></tr><tr><td align="left" valign="bottom">LV EF (%)</td><td align="char" char="plusmn" valign="bottom">64.7 ± 1.2</td><td align="char" char="plusmn" valign="bottom">51.9 ± 3.8</td><td align="char" char="." valign="bottom">&lt;0.01</td><td align="char" char="." valign="bottom">–19</td><td align="char" char="plusmn" valign="bottom">62.5 ± 0.9</td><td align="char" char="plusmn" valign="bottom">48.6 ± 1.7</td><td align="char" char="." valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">–22</td></tr><tr><td align="left" valign="bottom">LVAW systole (mm)</td><td align="char" char="plusmn" valign="bottom">1.40 ± 0.01</td><td align="char" char="plusmn" valign="bottom">1.44 ± 0.02</td><td align="char" char="." valign="bottom">0.09</td><td align="char" char="." valign="bottom">3</td><td align="char" char="plusmn" valign="bottom">1.39 ± 0.01</td><td align="char" char="plusmn" valign="bottom">1.52 ± 0.04</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">8</td></tr><tr><td align="left" valign="bottom">LVAW diastole (mm)</td><td align="char" char="plusmn" valign="bottom">0.88 ± 0.01</td><td align="char" char="plusmn" valign="bottom">1.01 ± 0.03</td><td align="char" char="." valign="bottom">&lt;0.01</td><td align="char" char="." valign="bottom">15</td><td align="char" char="plusmn" valign="bottom">0.91 ± 0.01</td><td align="char" char="plusmn" valign="bottom">1.08 ± 0.04</td><td align="char" char="." valign="bottom">&lt; 0.001</td><td align="char" char="." valign="bottom">20</td></tr><tr><td align="left" valign="bottom">LVPW systole (mm)</td><td align="char" char="plusmn" valign="bottom">1.35 ± 0.01</td><td align="char" char="plusmn" valign="bottom">1.39 ± 0.02</td><td align="char" char="." valign="bottom">0.17</td><td align="char" char="." valign="bottom">3</td><td align="char" char="plusmn" valign="bottom">1.34 ± 0.01</td><td align="char" char="plusmn" valign="bottom">1.42 ± 0.03</td><td align="char" char="." valign="bottom">0.4</td><td align="char" char="." valign="bottom">6</td></tr><tr><td align="left" valign="bottom">LVPW diastole (mm)</td><td align="char" char="plusmn" valign="bottom">0.87 ± 0.02</td><td align="char" char="plusmn" valign="bottom">0.98 ± 0.04</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">12</td><td align="char" char="plusmn" valign="bottom">0.88 ± 0.02</td><td align="char" char="plusmn" valign="bottom">1.08 ± 0.04</td><td align="char" char="." valign="bottom">&lt;0.001</td><td align="char" char="." valign="bottom">19</td></tr><tr><td align="left" valign="bottom">LVOT mean gradient</td><td align="char" char="plusmn" valign="bottom">2.4 ± 0.2</td><td align="char" char="plusmn" valign="bottom">6.8 ± 1.8</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">185</td><td align="char" char="plusmn" valign="bottom">2.3 ± 0.2</td><td align="char" char="plusmn" valign="bottom">4.9 ± 1.1</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">115</td></tr><tr><td align="left" valign="bottom">LVOT mean velocity</td><td align="char" char="plusmn" valign="bottom">768 ± 30</td><td align="char" char="plusmn" valign="bottom">1211 ± 162</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">58</td><td align="char" char="plusmn" valign="bottom">750 ± 37</td><td align="char" char="plusmn" valign="bottom">1066 ± 112</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">42</td></tr><tr><td align="left" valign="bottom">LVOT peak gradient</td><td align="char" char="plusmn" valign="bottom">5.8 ± 0.3</td><td align="char" char="plusmn" valign="bottom">15.7 ± 3.7</td><td align="char" char="." valign="bottom">0.03</td><td align="char" char="." valign="bottom">170</td><td align="char" char="plusmn" valign="bottom">5.5 ± 0.5</td><td align="char" char="plusmn" valign="bottom">13.3 ± 3.3</td><td align="char" char="." valign="bottom">0.04</td><td align="char" char="." valign="bottom">143</td></tr><tr><td align="left" valign="bottom">LVOT peak velocity</td><td align="char" char="plusmn" valign="bottom">1201 ± 35</td><td align="char" char="plusmn" valign="bottom">1870 ± 215</td><td align="char" char="." valign="bottom">0.01</td><td align="char" char="." valign="bottom">56</td><td align="char" char="plusmn" valign="bottom">1158 ± 52</td><td align="char" char="plusmn" valign="bottom">1732 ± 200</td><td align="char" char="." valign="bottom">0.02</td><td align="char" char="." valign="bottom">50</td></tr><tr><td align="left" valign="bottom">Aorta systole (mm)</td><td align="char" char="plusmn" valign="bottom">1.65 ± 0.04</td><td align="char" char="plusmn" valign="bottom">2.14 ± 0.10</td><td align="char" char="." valign="bottom">&lt;0.01</td><td align="char" char="." valign="bottom">30</td><td align="char" char="plusmn" valign="bottom">1.70 ± 0.04</td><td align="char" char="plusmn" valign="bottom">2.25 ± 0.12</td><td align="char" char="." valign="bottom">0.002</td><td align="char" char="." valign="bottom">32</td></tr><tr><td align="left" valign="bottom">Aorta diastole (mm)</td><td align="char" char="plusmn" valign="bottom">1.44 ± 0.04</td><td align="char" char="plusmn" valign="bottom">1.86 ± 0.07</td><td align="char" char="." valign="bottom">0.001</td><td align="char" char="." valign="bottom">30</td><td align="char" char="plusmn" valign="bottom">1.48 ± 0.04</td><td align="char" char="plusmn" valign="bottom">2.07 ± 0.13</td><td align="char" char="." valign="bottom">0.002</td><td align="char" char="." valign="bottom">40</td></tr><tr><td align="left" valign="bottom">First brachial arch (mm)</td><td align="char" char="plusmn" valign="bottom">0.78 ± 0.03</td><td align="char" char="plusmn" valign="bottom">1.06 ± 0.07</td><td align="char" char="." valign="bottom">0.003</td><td align="char" char="." valign="bottom">36</td><td align="char" char="plusmn" valign="bottom">0.78 ± 0.02</td><td align="char" char="plusmn" valign="bottom">1.09 ± 0.08</td><td align="char" char="." valign="bottom">0.004</td><td align="char" char="." valign="bottom">40</td></tr></tbody></table></table-wrap><p>Scatterplots of echocardiography data from 13 month animals show that most LOI phenotypes are heterogeneous and are not normally distributed (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Rather phenotypes for volume, mass, ejection fraction, and outflow tract velocity and turbulence are all bimodal: 6–7 animals display mild phenotypes, and 3–4 animals display extreme pathologies (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2A–D</xref>). The only exception to this pattern is seen in arterial diameter phenotypes. In this case, the variance among LOI animals is low (like their WT cohorts) and all the LOI animals display a pathologic phenotype (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2E,F</xref>).</p><p><xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> summarizes correlations between the various phenotypes identified by echocardiography. Cardiac function as measured by ejection fraction is inversely correlated with LV volume (RR = 0.81). However, function correlates only moderately with wall thickness (RR = 0.53) and not at all with outflow tract defects (RR = 0.02), or with aortic diameter (RR &lt; 0.01). Thus, LOI associated phenotypes are not uniformly penetrant. Rather, each mouse presents a distinct array of defects. The only invariant is that all LOI mice have arterial diameters larger than their wild-type counterparts.</p><p>The right-hand columns in <xref ref-type="table" rid="table1">Table 1</xref> summarize echocardiography results from the same mice at 16 months of age. We observed the same ventricular abnormalities: reduced ejection fraction, increased chamber size, and increased wall thickness. However, on scatter plots, we see that wild-type and mutant animals now show non-overlapping phenotypes, consistent with the idea that ventricular failure is progressing in LOI mice (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Note that the LOI mouse with the poorest function at 13 months (25 % EF) died prior to this second analysis.</p><p>Finally, in vivo analyses at 19 months identified significant pathological reductions in both systolic blood pressure (WT = 105 ± 2, LOI = 93 ± 3, p=0.01) and pulse pressure (WT = 37 ± 1, LOI = 28 ± 1, p&lt;0.001) in mutant mice (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>). These data confirm that <italic>H19/Igf2</italic> LOI has a substantial effect on cardiovascular function.</p><p>As described above, increased artery diameter is a phenotype where by 13 months, LOI and WT mice sorted into phenotypically distinct cohorts. This suggested that abnormal blood vessel structure might be a relatively primary defect. We focused additional attention to this phenotype and measured outer diameters of isolated ascending aorta and carotid arteries in response to applied pressures on a pressure myograph (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4A</xref>). Arteries from LOI mice are larger in diameter across all applied pressures. Moreover, across normal physiological pressure ranges (75–125 mmHg) arteries from mutant mice are more sensitive to changes in pressure and lumens reach their maximum diameter at lower pressures. They are appropriately distensible at low (elastic) pressures but are stiffer than WT vessels over higher pressure intervals, including most physiologic pressures (<xref ref-type="fig" rid="fig3">Figure 3F</xref>, <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4B</xref>).</p><p>In sum, <italic>H19/Igf2</italic> LOI in mice results in transient neonatal cardiomegaly and then a progressive cardiomyopathy. Note that results shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> and in <xref ref-type="table" rid="table1">Table 1</xref> describe comparisons of age-matched male mice. Adult LOI females consistently showed relatively weak phenotypes and p-values were not significant (data now shown). However, neonatal hypertrophy and hyperplasia occurs in both male and female pups. This apparent paradox was the first clue that the relationship between the neonatal hypertrophy and the adult disease phenotypes was not straightforward.</p></sec><sec id="s2-2"><title>Hypertrophy and hyperplasia in neonatal LOI mice is dependent on hyperactivation of mTOR/AKT signaling by increased dosage of IGF2 peptide</title><p>To understand the specific roles for mis-expression of <italic>Igf2</italic> and of <italic>H19</italic> in neonatal cardiomegaly, we performed two genetic analyses. First, we rescued <italic>H19</italic> expression in an LOI background by introducing a 140 kb H19 Bacterial Artificial Chromosome (H19 BAC) (<xref ref-type="bibr" rid="bib38">Kaffer et al., 2001</xref>; <xref ref-type="bibr" rid="bib37">Kaffer et al., 2000</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>) but still saw cardiomyocyte hypertrophy and hyperplasia in neonates (<xref ref-type="fig" rid="fig2">Figure 2A,C</xref>). Second, we tested the effect of removing <italic>H19</italic> in a background where <italic>Igf2</italic> remains monoallelic by comparing <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) with wild-type littermates. (Reduced expression of <italic>H19</italic> lncRNA in <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> is shown in <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>.) Loss of <italic>H19</italic> lncRNA does not result in neonatal cardiomyocyte hypertrophy or hyperplasia (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Altogether, we conclude that loss of <italic>H19</italic> lncRNA does not contribute to neonatal hypergrowth. Rather, this neonatal hypertrophy is dependent only upon biallelic (2× dosage) <italic>Igf2</italic> transcription.</p><p>IGF2 peptide works by binding and activating InsR and IgfR kinases and mTOR/AKT signaling is a known downstream target of these receptor kinases (<xref ref-type="bibr" rid="bib4">Bergman et al., 2013</xref>). In addition, studies document the role of AKT/mTOR signaling in cardiomyocyte cell division and hypertrophy (<xref ref-type="bibr" rid="bib23">Geng et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Li et al., 2011</xref>; <xref ref-type="bibr" rid="bib70">Sciarretta et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Shen et al., 2020</xref>; <xref ref-type="bibr" rid="bib83">Wang et al., 2019</xref>). Consistent with a critical role for AKT/mTOR signaling in LOI-dependent neonatal hypertrophy, hearts from LOI neonates show increased levels of phosphorylated AKT and of phosphorylated S6K1, a downstream marker for mTORC1 activity (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Moreover, the LOI cellular hypertrophy and pAKT hyperactivation phenotypes can be phenocopied by treatment of wild-type primary cardiomyocytes with IGF2 peptide. However, IGF2 action is blocked by BMS-754807, a specific inhibitor of the receptor kinase, or by treatment with rapamycin, an mTOR signaling pathway inhibitor (<xref ref-type="fig" rid="fig2">Figure 2G and H</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>).</p><p><italic>Igf2</italic> is widely expressed in the embryo. In fact, expression of <italic>Igf2</italic> is low in the heart relative to other tissues, especially liver and skeletal muscle (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>), which are believed to be the major source of circulating IGF2 peptide. Within the heart, IGF2 originates in both cardiomyocytes but also in endothelial cells (<xref ref-type="bibr" rid="bib71">Shen et al., 2020</xref>). To assess the role of biallelic expression of <italic>Igf2</italic> in the cardiomyocytes themselves, we crossed <italic>H19<sup>ΔICR</sup>/H19<sup>ICRflox</sup></italic> females with <italic>H19<sup>+</sup>/H19<sup>+</sup></italic> males carrying the Myh6-Cre transgene. <italic>H19<sup>ICRflox</sup></italic> is an allele where the <italic>H19ICR</italic> is flanked with <italic>loxP</italic> sites, so that cre recombination results in deletion of the <italic>ICR</italic> (<xref ref-type="bibr" rid="bib73">Srivastava et al., 2000</xref>). We used PCR analyses to demonstrate that the transgene drives efficient ICR deletion in the heart but not in other tissues tested (skeletal muscle, liver, kidney, brain, thymus, spleen, and lung). Our cross generated wild-type mice (<italic>H19<sup>ICRflox</sup>/H19<sup>+</sup></italic>) and two kinds of LOI controls (<italic>H19<sup>ΔICR</sup>/H19<sup>+</sup>;+ Myh6</italic> Cre and <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic>) that we compared with experimental mice that had cardiomyocyte-specific LOI (<italic>H19<sup>ICRflox</sup>/H19<sup>+</sup>;+ Myh6</italic> Cre). Cardiomyocyte-specific ICR deletion does not cause hypertrophy. Rather, <italic>H19<sup>ICRFlox</sup>/H19<sup>+</sup> Myh6</italic> Cre mice were indistinguishable from their wild-type littermates (<xref ref-type="fig" rid="fig2">Figure 2E,F,I,J</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>).</p><p>Note that our data demonstrate that the effects of LOI on neonatal cardiomyocytes are cell non-autonomous but do not rule out a cell autonomous role in other cell types, including cardiac endothelium.</p><p>Cardiac disease in adults is dependent only on loss of H19 lncRNA expression. Biallelic Igf2 and the resultant hypertrophy in neonatal hearts are not relevant to the adult LOI phenotype.</p><p>While the <italic>H19</italic> BAC transgene does not prevent neonatal cardiomegaly, it does successfully prevent adult pathologies. That is, hearts from 6 month LOI mice carrying the <italic>H19</italic> transgene are not enlarged as determined by heart weight/tibia length ratios (LOI = 12.9 ± 0.6 mg/mm, N = 3; LOI+ H19 BAC transgene = 11.5 ± 0.7, N = 3; p&lt;0.05), are not fibrotic (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>), and do not express cardiomyopathy markers (<xref ref-type="fig" rid="fig4">Figure 4C</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Thus, loss of <italic>H19</italic> is necessary to induce LOI cardiomyopathies.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>LOI pathologies in adult mice are <italic>H19</italic>-dependent.</title><p>(<bold>A–C</bold>) An <italic>H19</italic> transgene rescues pathologies in LOI mice. Phenotypes of LOI mice or their LOI littermates that also carry an H19 Bacterial Artificial Chromosome transgene that restores wild-type levels of <italic>H19</italic> RNA (LOI+ H19 BAC). (<bold>D–G</bold>) <italic>H19</italic> deletion is sufficient to cause cardiac pathologies. Phenotypes in wild-type (WT) mice and in littermates carrying the <italic>H19ΔEx1</italic> deletion. For histology (<bold>A, B, E, F</bold>) hearts were isolated from 6 month old animals and transverse sections collected midway along the longitudinal axes before staining with hematoxylin and eosin (<bold>D</bold>) or with Masson’s trichrome (<bold>A, B, E, F</bold>) Statistical significance was analyzed using Student’s t-test type 2. For immunoblotting (<bold>C, G</bold>), hearts were isolated from 1 year animals and investigated for ANP, Myh7, Serca2, Cleaved Caspase-3, and Cleaved PARP. β-Tubulin is a loading control. See <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> for quantified data.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Pathologies in LOI mice are caused by decreased function of the H19 lncRNA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>H19 dependent changes in protein expression in adult mice – quantitated Western blots.</title><p>(<bold> A</bold>) Expression of heart failure biomarkers in hearts isolated from adult LOI and in LOI+ H19 BAC transgenic littermates. See <xref ref-type="fig" rid="fig4">Figure 4C</xref> for representative blot. Biological replicates = 3. (<bold>B</bold>) Expression of heart failure biomarkers in hearts isolated from adult wild-type and H19<sup>ΔEx1</sup>/H19<sup>+</sup> littermates. See <xref ref-type="fig" rid="fig4">Figure 4F</xref> for blot. Biological replicates = 3. For each panel, quantitation was by NIH Image J. Counts were normalized to β-tubulin and statistical significance was analyzed by Student’s t test type 1.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig4-figsupp1-v2.tif"/></fig></fig-group><p>We next investigated whether loss of <italic>H19</italic> is sufficient to induce pathologies and also investigated exactly which <italic>H19</italic> RNA was important. The <italic>H19</italic> gene encodes a 2.3 kb lncRNA which is exported to the cytoplasm but also is the precursor for microRNAs, <italic>Mir675-5p</italic> and <italic>Mir675-3p</italic> (<xref ref-type="bibr" rid="bib7">Cai and Cullen, 2007</xref>). Since LOI mice show reduced levels of both the lncRNA and of <italic>Mir675-3p</italic> and <italic>-5</italic> p and because the H19 BAC transgene restores expression of both the lncRNA and the <italic>Mir675</italic> microRNAs, these models were not helpful in determining which RNA species prevents cardiac pathology. The <italic>H19ΔEx1</italic> allele is a 700 bp deletion of the 5’ end of exon one that leaves bases encoding the <italic>Mir675-3p</italic> and <italic>Mir675-5p</italic> intact (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). This <italic>ΔEx1</italic> deletion does not prevent <italic>H19</italic> transcription but rather, reduces <italic>H19</italic> lncRNA levels by destabilizing the truncated transcript (<xref ref-type="bibr" rid="bib74">Srivastava et al., 2003</xref>), raising the possibility that the <italic>ΔEx1</italic> mutation might affect only the lncRNA. In fact, we show here that levels of <italic>Mir675-5p</italic> and <italic>-3</italic> p are unaltered in <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). Yet, 6-month-old <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> mice display LOI cardiac pathologies including hypertrophy (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), fibrosis (<xref ref-type="fig" rid="fig4">Figure 4E,F</xref>), and expression of disease markers (<xref ref-type="fig" rid="fig4">Figure 4G</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>). Thus, we conclude that loss of <italic>H19</italic> lncRNA is sufficient to induce cardiomyopathy in adult mice.</p><p>In addition to establishing the critical importance of <italic>H19</italic> lncRNA, these genetic experiments also uncouple neonatal hypertrophy and adult pathology: neonatal LOI+ H19 BAC mice show hypertrophy but do not develop adult pathologies, while neonatal <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> have normal-sized hearts but do develop pathologies. Thus, neonatal cardiomegaly is not a risk factor for adult pathologies.</p></sec><sec id="s2-3"><title>H19 lncRNA regulates the frequency of endothelial to mesenchymal transition in mice and in isolated primary endothelial cell cultures</title><p><italic>H19</italic> expression is not uniform throughout the heart but rather restricted to endothelial cells (ECs) (<xref ref-type="fig" rid="fig5">Figure 5A,B</xref>). In fetal and neonatal hearts <italic>H19</italic> is expressed in all endothelial cells including microvasculature. In adults, <italic>H19</italic> expression is patchy and patterns vary between mice but are always restricted to endocardium and endothelial cells lining major coronary vessels (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Localization was confirmed in vasculature by co-staining for both endothelial and smooth muscle markers. For example, in coronary vessels, <italic>H19</italic> RNA expression exclusively overlapped with endothelial specific marker von-Willebrand’s factor (<xref ref-type="fig" rid="fig5">Figure 5B</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>H19</italic> influences gene expression and cell fate in cardiac endothelial cells.</title><p>(<bold>A</bold>) In situ staining for <italic>H19</italic> (brown) in hearts from wild-type P1 neonates or 6 month adults. (<bold>B</bold>) Combined in situ and immunohistochemistry for hearts isolated from wild-type and <italic>H19ΔEx1/H19+</italic> littermates at 6 months shows expression of <italic>H19</italic> is concentrated in endothelial cells. Sections were stained for <italic>H19</italic> lncRNA and then with antibodies to the endothelial marker, vWF (von Willebrand factor), or to the smooth muscle marker, α−SMA (alpha smooth muscle actin). (<bold>C</bold>) MA blot showing differences in expression of polyadenylated RNAs in <italic>H19</italic>-deficient endothelial cells. Endothelial cells were isolated from wild-type (N = 4) and <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> (N = 3) P2 neonatal hearts based on CD31 expression. RNAs were isolated and polyadenylated transcripts were quantitated. Genes marked in red are significantly differentially expressed at FDR &lt; 0.05. Gene ontology analyses are described in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>. (<bold>D</bold>) Transient transfection of <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> cardiac endothelial cells with an <italic>H19</italic>-expression vector rescues expression of key EndMT genes. Cardiac endothelial cells were isolated from wild-type and <italic>H19</italic>-deficient P2 hearts as described in (<bold>D</bold>) and transfected with empty expression vector (pcDNA3) or with pcDNA3 carrying mouse <italic>H19</italic> gDNA (pcDNA3-H19). After + hours in culture, RNA was extracted and cDNAs synthesized and analyzed for <italic>H19</italic>, <italic>SM22α</italic>, <italic>Snail</italic>, or <italic>Slug</italic>. For each gene, cDNA levels were normalized to <italic>GAPDH</italic> and then to the levels seen in wild-type cells transfected with pcDNA3 only. (<bold>E, F</bold>). Increased frequency of EndMT transitioning cells in <italic>H19</italic>-deficient mice. (<bold>E</bold>) Hearts from wild type and <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> were isolated at e14.5, P1, and at 6 months. Sections were probed for endothelial cell markers (CD31 or IB4) and for mesenchymal markers (αSMA or SM22α) to identify cells co-expressing these genes. (<bold>F</bold>) Frequencies of cells co-expressing endothelial and mesenchymal markers in adult and P1 hearts. The role of <italic>H19</italic> was determined by three independent comparisons: wild type vs. <italic>Η19Δ<sup>Ex1</sup>/H19<sup>+</sup></italic>, LOI vs LOI+ H19 BAC, wild type vs LOI. (<bold>D, F</bold>). Statistical significance was evaluated using Student’s t-test type 2.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>H19 regulates gene expression and cell fate in cardiac endothelial cells.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Visual representation of Gene Ontology analysis for endothelial cells isolated from wild-type (N = 4) and H19<sup>ΔEx1</sup>/H19<sup>+</sup> (N = 3) P2 neonatal hearts.</title><p>RNAs were isolated and polyadenylated transcripts were quantitated. Cnetplot depicts linkages of genes and biological concepts as a network. Nodes identify complex associations of genes that contribute to a functional term within a pathway. GO: Biological Process indicates enriched mesenchymal biological markers and regulation of endothelial proliferation genes. GO: Cellular Components indicate enrichment in extracellular matrix genes. GO: Molecular function indicates enrichment in extracellular matrix and TGF-beta binding genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig5-figsupp1-v2.tif"/></fig></fig-group><p>To identify a possible function for <italic>H19</italic> RNA, we performed transcriptomic analyses comparing RNAs isolated from wild-type and <italic>H19</italic>-deficient P1 hearts. Using whole heart extracts, we did not identify significant differences in gene expression. We next compared RNAs isolated from purified ECs. Hearts were dissociated into single cells using enzyme digestion and mechanical agitation and then endothelial cells were isolated based on expression of CD31 antigen. About 30,000 cells per neonatal heart were isolated to &gt;95% purity. RNA sequencing identified 228 differentially expressed genes (DEGs) with adjusted p-values of &lt;0.1, including 111 upregulated and 117 downregulated transcripts (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). GO analysis for biological, cellular, and molecular pathways gives evidence for a change in cellular identity (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Specifically, enriched biological pathways included positive regulation of mesenchymal cell proliferation, positive regulation of endothelial cell migration, and cell adhesion (n = 36, p-adj = 0.003). Cellular pathways showed enrichment for genes coding for extracellular matrix (n = 42, p-adj = 1.83E-10). Enriched molecular function categories include extracellular matrix binding and TGFβ binding (n = 7, p-adj = 0.0001; n = 5, p-adj = 0.1), as well as other pathways that are especially active during endothelial to mesenchymal transition (EndMT). EndMT is not an identifiable GO term, however, we conducted a PubMed search of the 188 DEGs described in the PubMed literature database and noted that 63 DEGs were implicated in EndMT as either players in driving the transition or as markers. Some examples include <italic>Transforming growth factor beta receptor 3 (Tgfbr3,</italic> up 1.5×, padj = 0.01)<italic>, Collagen Type XIII α1 chain</italic> (<italic>Col13a1,</italic> up 2.0×, padj = 4.2E-09), <italic>Bone Morphogenic Protein 6</italic> (<italic>Bmp6</italic>, down 0.6×, padj = 7.0E-05), <italic>Latent Transforming Growth Factor Binding Protein 4</italic> (<italic>Ltbp4</italic>, down 0.5×, padj = 0.008)<italic>, Connective Tissue Growth Factor</italic> (<italic>Ctgf</italic>, down 0.7×, padj = 0.06), <italic>Slit Guidance Ligand 2, (Slit2,</italic> up 1.6×, padj = 2.5E-05), and α2 macroglobin (<italic>A2m</italic>, down 0.6×, 5.6E-05). Due to the results of the GO term analysis as well as the PubMed search, we speculated that <italic>H19</italic> might play a role in regulating EndMT.</p><p>To directly test the role of <italic>H19</italic> in regulating EC gene biology, we isolated primary ECs from wild-type and <italic>H19</italic>-deficient P2 littermates and transfected with an <italic>H19</italic> expression vector or with an empty control vector and then assayed gene expression after 24 hr. <italic>H19</italic> expression reduces expression of a mesenchymal cell marker (<italic>SM22α</italic>) and of genes encoding transcription factors critical for EndMT (<italic>Snail</italic> and <italic>Slug</italic>) (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>EndMT is an essential part of the normal development of many tissues/organs including heart. For example, EndMT is critical in cardiac valve development (<xref ref-type="bibr" rid="bib43">Kisanuki et al., 2001</xref>; <xref ref-type="bibr" rid="bib55">Markwald et al., 1977</xref>). Studies also report that EndMT contributes to cardiac diseases including cardiac fibrosis, valve calcification, and endocardial elastofibrosis (<xref ref-type="bibr" rid="bib19">Evrard et al., 2016</xref>; <xref ref-type="bibr" rid="bib26">Goumans et al., 2008</xref>; <xref ref-type="bibr" rid="bib66">Piera-Velazquez et al., 2011</xref>; <xref ref-type="bibr" rid="bib88">Zeisberg et al., 2007</xref>). During the actual EC transition, cells will transiently express endothelial markers (like CD31or IB4) simultaneously with mesenchymal markers (like aSMA or SM22a). To understand the impact of <italic>H19</italic> deficiency on EC transition in vivo, we fixed and sectioned hearts isolated at several developmental stages from <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> and their wild-type littermates mice and looked for co-staining of these endothelial and mesenchymal markers. At each stage, we focused on the regions of the heart where <italic>H19</italic> expressing cells were particularly abundant, assuming that this is where a phenotype would be most readily observed. In e14.5 embryos, we looked at endocardium, epicardium, valves, and blood vessels. In P1 embryos, we looked at endocardium, valves, and blood vessels. In adult hearts, we looked at endocardium. Comparable sections for wild-type and mutant mice were identified by a cardiac pathologist blinded to genotype before we stained for EC and mesenchymal markers. In each stage. we noted significant changes in co-staining frequency indicating that the likelihood of EC cell transition is increased in the absence of <italic>H19</italic> (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>). We confirmed that these results through independent analyses that compared LOI mice with their wild-type littermates (<italic>H19<sup>ΔICR</sup>/H19+</italic> vs. <italic>H19<sup>+</sup>/H19<sup>+</sup></italic>) and that compared LOI mice with LOI littermates that also carried the H19 BAC transgene <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic> vs <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic> H19 BAC Transgene (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p></sec><sec id="s2-4"><title>Mirlet7 binding sites on the H19 lncRNA are essential for normal cardiac physiology</title><p><italic>H19</italic> lncRNA is known to physically bind <italic>Mirlet7g</italic> (<italic>let-7g</italic>) and <italic>Mirlet7i (let-7i</italic>) in exon one and <italic>Mirlet7e</italic> (<italic>let-7e</italic>) in exon four in mice (<xref ref-type="bibr" rid="bib40">Kallen et al., 2013</xref>). One proposed mechanism for <italic>H19</italic> lncRNA function is that it regulates <italic>Mirlet7</italic> microRNAs via these interactions to modulate their biological activities. <italic>Mirlet7</italic> miRNAs are known to play a role in cardiovascular diseases including cardiac hypertrophy, cardiac fibrosis, dilated cardiomyopathy, and myocardial infarction (<xref ref-type="bibr" rid="bib2">Bao et al., 2013</xref>).</p><p>To test the role of <italic>H19’s Mirlet7</italic> binding in preventing cardiomyopathy, we used CRISPR/Cas9 genome editing to delete <italic>Mirlet7</italic> binding sites in the <italic>H19</italic> gene (<xref ref-type="fig" rid="fig1">Figures 1A</xref> and <xref ref-type="fig" rid="fig6">6A</xref>). Mice carrying this mutation (<italic>H19ΔLet7/ H19ΔLet7</italic>) express <italic>H19</italic> at wild-type levels (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), which shows that the deletions do not disrupt lncRNA expression or stability. We used sequence-specific biotinylated oligonucleotides to purify <italic>H19</italic> lncRNA from extracts prepared from wild-type and from <italic>H19<sup>Δlet7</sup>/H19<sup>Δlet7</sup></italic> cells and assayed for co-purification of <italic>Mirlet7</italic> microRNAs. These experiments provided direct biochemical evidence that <italic>H19</italic> and <italic>Mirlet7</italic> RNAs do physically associate and also that these interactions are lost in our <italic>H19Δlet7</italic> deletion model (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>H19</italic>’s <italic>Mirlet7</italic> binding domains are essential for normal function.</title><p>(<bold>A</bold>) The <italic>H19ΔLet7</italic> allele was generated by deleting 25 and 48 bp sequences within exons 1 and 4 to eliminate binding sites for <italic>Mirlet7g</italic>, <italic>Mirlet7i,</italic> and <italic>Mirlet7e</italic> miRNAs. (<bold>B</bold>) The <italic>H19ΔLet7</italic> allele is expressed at wild-type levels. RNAs were isolated from hearts from <italic>H19<sup>ΔLet7</sup>/H19<sup>+</sup></italic> and quantitated by qRT-PCR, normalizing first to <italic>GAPDH</italic> and then to the levels of <italic>H19</italic> observed in <italic>H19<sup>+</sup>/H19<sup>+</sup></italic>. Similarly, <italic>Igf2</italic> is expressed at equivalent levels in wild-type and mutant mice. Thus phenotypes associated with the <italic>H19Δlet7</italic> allele should be ascribed to changes in <italic>H19</italic> function and not to changes in <italic>H19</italic> levels or in <italic>Igf2</italic> expression. See <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref> for experiments demonstrating that the <italic>H19Δlet7</italic> lncRNA cannot interact with <italic>Mirlet7</italic> miRNAs. (<bold>C</bold>) Transverse sections were collected midway along the longitudinal axis from hearts collected from 12-month-old wild-type (N = 4) and mutant (N = 3) littermates and stained with hematoxylin and eosin. (<bold>D</bold>) Fiber diameters were quantitated using three sections per mouse. (<bold>E, F</bold>). Masson’s trichrome staining of sections described in panel (<bold>C</bold>) Red, muscle fibers; blue, collagen. Sections from three wild-type and four mutant littermates were used to calculate fibrosis. (<bold>G</bold>) Immunoblot analyses of whole heart extracts prepared from 12 month WT (N = 3) and mutant littermates (N = 3). Altered expression of ANP, Myh7, Cleaved Caspase-3, Cleaved Caspase-7, and Cleaved PARP. β-tubulin is a loading control. Quantified data is presented in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>. Statistical significance was evaluated with Student’s t-test type 2.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Mirlet7 binding sites on the H19lncRNA are essential to prevent cardiomyopathy.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title><italic>Mirlet7e, -g, and -i miRNAs copurify with wild-type H19 lncRNA, but not with the H19Δlet7 mutant RNA</italic>.</title><p>Primary myoblasts were prepared from wild-type and from <italic>H19<sup>Δlet7</sup>/H19<sup>Δlet7</sup></italic> neonatal littermates. (<bold>A, C, E, G, I and K</bold>) (Before Pulldown) RNAs in total cell extracts were quantitated by qRT-PCR. <italic>H19</italic>, <italic>MyoG</italic>, and <italic>Mirlet7</italic> RNAs were normalized first to <italic>GAPDH</italic> and then to the levels seen in wild-type samples. <italic>GAPDH</italic> was normalized first to total cellular RNA and then to the levels seen in wild-type samples. Note that expression of <italic>H19</italic> lncRNA (<bold>A</bold>) and of <italic>Mirlet7</italic> miRNAs (<bold>C, E, G</bold>) is equivalent in wild-type and mutant cells. (<bold>B, D, F, H, J, and L</bold>) (After Pulldown) Purification of <italic>H19</italic> was performed as described in Methods. Briefly, cell extracts were crosslinked with paraformaldehyde and then incubated with a set of biotinylated oligonucleotides that are specific to <italic>H19</italic> lncRNA (h19). As a control, extracts were alternatively incubated with an oligonucleotide designed to exclude binding to <italic>H19</italic> lncRNA (con). After purification with biotin beads, crosslinks were reversed and pelleted RNAs were quantitated by qRT-PCR and normalized to levels in total extracts. (<bold>B</bold>) Efficient purification of <italic>H19</italic> lncRNA from both wild-type and mutant extracts. (<bold>D, F, and H</bold>) <italic>Mirlet7</italic> miRNAs co-purify only with wild-type and not with <italic>H19Δlet7</italic> lncRNA. (<bold>J</bold>) The effect of the <italic>Δlet7</italic> deletion on <italic>H19</italic> interactions with other RNAs is specific: <italic>MyoG</italic> RNA copurifies with both wild-type and mutant <italic>H19</italic> lncRNAs. (<bold>L</bold>) <italic>GAPDH</italic> is a negative control that co-purifies with neither wild type nor mutant H19. Three independently derived cell lines of each genotype were analyzed. Statistical significance was evaluated using a Student’s t-test type 2. APD, after pulldown; BPD, before pulldown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>H19-dependent changes in protein expression in adult mice – quantitated western blots.</title><p>Expression of heart failure biomarkers in hearts isolated from adult <italic>wild-type</italic> and <italic>H19<sup>Δlet7</sup>/H19<sup>Δlet7</sup></italic> littermates. See <xref ref-type="fig" rid="fig4">Figure 4F</xref> for blot. Biological replicates = 3. Gels were loaded based on total protein concentration in each extract and blots were quantified using NIH Image J software. Counts were normalized to β-tubulin, and statistical significance was evaluated by Student’s t-test type 2.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67250-fig6-figsupp2-v2.tif"/></fig></fig-group><p>One year old <italic>H19<sup>ΔLet7</sup>/H19<sup>ΔLet7</sup></italic> mice displayed cardiomegaly as measured by a 32% increase in heart weight/tibia length ratios (wild type = 7.5 ± 1.7 mg/mm, N = 4; <italic>H19<sup>ΔLet7</sup>/H19<sup>+</sup></italic> = 9.9 ± 2.2 mg/mm, N = 5; p=0.007). Transverse sections also suggested hypertrophy (<xref ref-type="fig" rid="fig6">Figure 6C</xref>), which was quantified as increased fiber diameter (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). The cardiac hypertrophy in <italic>H19<sup>ΔLet7</sup>/H19<sup>ΔLet7</sup></italic> mice was accompanied by increased interstitial and perivascular fibrosis (<xref ref-type="fig" rid="fig6">Figure 6E,F</xref>). The pathologic nature of the observed cardiac myopathies in these mutant mice was confirmed by the increased levels of cardiomyopathy markers (<xref ref-type="fig" rid="fig6">Figure 6G</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). Thus our results support a role for <italic>Mirlet7</italic> miRNA binding to <italic>H19 lncRNA</italic> in preventing cardiomyopathies.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>BWS is an overgrowth disorder with significant patient to patient variation in disease symptoms (<xref ref-type="bibr" rid="bib34">Jacob et al., 2013</xref>). An explanation for some of this variability is that independent molecular mechanisms for BWS exist (<xref ref-type="bibr" rid="bib84">Weksberg et al., 2010</xref>). More than 50% of BWS cases are associated with epigenetic lesions that disrupt expression of <italic>CDKN1C</italic>, an imprinted gene closely linked to <italic>IGF2/H19</italic> but under control of its own <italic>ICR (IC2</italic>). (More rarely, BWS cases are associated with pathogenic lesions in the <italic>CDKN1C</italic> peptide coding sequences.) About 5% of BWS cases are associated with disrupted imprinting at the <italic>IGF2/H19</italic> locus. About 20% of cases are associated with paternal uniparental disomy of the entire region (potentially affecting both <italic>CDKN1C</italic> and <italic>IGF2/H19</italic>) (IC1 and IC2), and another 20% of cases are of unknown origin.</p><p>There are conflicting studies regarding the correlation of artificial reproductive technology (ART) in the development of BWS. <xref ref-type="bibr" rid="bib14">Doornbos et al., 2007</xref> suggested no direct effect on the increase of imprinted diseases after correcting for the increased fertility problems of the parents. However, more recent studies have examined the effect of ART on epigenetic changes (<xref ref-type="bibr" rid="bib62">Odom and Segars, 2010</xref>) and suggest a 6- to 10-fold increased risk for BWS specifically because of the increased chance that <italic>IGF2/H19</italic> imprinting is disrupted (<xref ref-type="bibr" rid="bib30">Hattori et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Johnson et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Mussa et al., 2017</xref>). Interestingly, BWS patients associated with ART are more likely to show cardiac problems (<xref ref-type="bibr" rid="bib76">Tenorio et al., 2016</xref>), suggesting a role for <italic>IGF2/H19</italic> expression in normal heart development and function.</p><p>In this study, we characterize a mouse model for <italic>Igf2/H19</italic> LOI. This model deletes the <italic>Imprinting Control Region</italic> upstream of the <italic>H19</italic> promoter and recapitulates the molecular phenotype of BWS patients: biallelic (i.e. 2× dosage) <italic>IGF2</italic> and reduced <italic>H19</italic> RNA. Here we show that this model not only phenocopies the transient cardiomegaly observed in neonates but also displays cardiovascular dysfunctions that are only rarely observed in patients.</p><p>To elucidate the molecular and developmental etiology of these cardiovascular phenotypes, we characterized two additional mouse models that independently altered expression of <italic>Igf2</italic> and of <italic>H19</italic>. These genetic analyses demonstrated that overexpression of <italic>Igf2</italic> and loss of <italic>H19</italic> play distinct roles in driving BWS cardiac phenotypes. In neonates, increased levels of circulating IGF2 results in hyperactivation of mTOR signaling in cardiomyocytes and thus leads to cardiomyocyte hyperplasia and cellular hypertrophy but the resultant cardiomegaly in mice is transient. As in humans, expression of <italic>Igf2</italic> in mice is strongly downregulated after birth and organ sizes return toward normal. Loss of <italic>H19</italic>, however, results in progressive cardiac pathology. Aged <italic>H19</italic> deficient mice show increased fibrosis, expression of markers indicative of cardiac failure, abnormal echocardiography phenotypes, low blood pressure, and aberrant vasculature. Thus, in the mouse LOI model, disease phenotypes are not restricted to fetal and neonatal stages. It will be interesting and important to assess whether this is true in other mammals.</p><p>In hearts, <italic>H19</italic> expression is restricted to endothelial cells. To understand the significance of <italic>H19</italic> expression we isolated cardiac ECs from wild-type and mutant neonates. Transcriptome analyses showed altered expression of genes associated with endothelial to mesenchymal transition, suggesting that <italic>H19</italic> might help regulate EC cell fate. Supporting this idea, we saw that forcing expression of <italic>H19</italic> in primary ECs prevents activation of mesenchymal gene expression patterns. Finally, we saw that <italic>H19</italic>-deficient mice show significant increases in the frequency of EC cells simultaneously expressing mesenchymal markers.</p><p>The ability of some ECs to transition of mesenchymal cells is necessary for normal development and thus can be assumed to be an essential property of ECs. The phenotypes of <italic>H19</italic>-deficient mice do not suggest that <italic>H19</italic> lncRNA is the single key molecule regulating EC cell fate. Even in LOI mice, EndMT is almost always occurring only when developmentally appropriate. Rather, our data indicate that <italic>H19</italic> RNA levels play a role in modulating the fate decision, so that cells lacking <italic>H19</italic> are modestly but measurably more likely to switch toward a transitional state where both EC and mesenchymal markers are expressed. It is interesting to note one commonality of key pathways disrupted by loss of <italic>H19</italic> lncRNA is that they share regulation by TGFβ signaling, suggesting that the observed 50 % reduction in expression of TGFβ receptors might be a key phenotype in <italic>H19</italic>-deficient ECs (<xref ref-type="bibr" rid="bib26">Goumans et al., 2008</xref>).</p><p>Our findings extend earlier studies showing patterns of <italic>H19</italic> expression in development and in response to injury suggesting a role for <italic>H19</italic> in vascular physiology and pathology (<xref ref-type="bibr" rid="bib35">Jiang et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Kim et al., 1994</xref>). Moreover, <xref ref-type="bibr" rid="bib80">Voellenkle et al., 2016</xref> recently described a role for lncRNAs including <italic>H19</italic> in the physiology of umbilical vein endothelial cells.</p><p>Our results also agree with in vitro studies that demonstrated an important role for <italic>H19</italic> in regulating EMT in cancer cells (<xref ref-type="bibr" rid="bib50">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Ma et al., 2014</xref>; <xref ref-type="bibr" rid="bib57">Matouk et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Matouk et al., 2014</xref>; <xref ref-type="bibr" rid="bib85">Wu et al., 2019</xref>; <xref ref-type="bibr" rid="bib90">Zhang et al., 2018</xref>). In these previous analyses, <italic>H19</italic> function was determined by transfecting cancer cells with <italic>H19</italic>-expression vectors and analyzing cell motility and gene expression. However, in contrast to our findings that activation of mesenchymal expression is associated with loss of <italic>H19</italic>, these in vitro analyses find EMT is induced by increasing <italic>H19</italic> RNA. This discrepancy emphasizes the useful role for genetic animal models in addressing developmental disorders where phenotypes are coming from cumulative changes in multiple cell types and over long periods of time. In animal models, observed phenotypes are due to the cumulative effect of the mutation in many cell types and over developmental time. In vitro studies of H19 have focused on the effect of acute changes in levels of <italic>H19</italic> in a single cell type.</p><p>Our analyses cannot address the fate of cells that co-express EC and mesenchymal markers. Do they all proceed toward full EndMT, do they return toward EC fates, or do they teeter in between? These questions can be addressed in future experiments using conditional <italic>H19</italic> deletion alleles and cell fate markers.</p><p><italic>H19</italic> can be a very abundant transcript. In neonatal ECs, <italic>H19</italic> lncRNA represents about 1% of all polyadenylated RNA. Yet its biochemical functions remain unclear. Various studies support the idea that <italic>H19</italic> functions as a microRNA precursor (<xref ref-type="bibr" rid="bib7">Cai and Cullen, 2007</xref>; <xref ref-type="bibr" rid="bib12">Dey et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Keniry et al., 2012</xref>), as a p53 protein inhibitor (<xref ref-type="bibr" rid="bib28">Hadji et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Park et al., 2017</xref>; <xref ref-type="bibr" rid="bib86">Yang et al., 2012</xref>; <xref ref-type="bibr" rid="bib89">Zhang et al., 2017</xref>), as a regulator of DNA methylation (<xref ref-type="bibr" rid="bib93">Zhou et al., 2019</xref>; <xref ref-type="bibr" rid="bib92">Zhou et al., 2015</xref>), and as a modulator of <italic>Mirlet7</italic> microRNA functions (<xref ref-type="bibr" rid="bib22">Gao et al., 2014</xref>; <xref ref-type="bibr" rid="bib24">Geng et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Kallen et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Peng et al., 2017</xref>; <xref ref-type="bibr" rid="bib91">Zhang et al., 2019</xref>; <xref ref-type="bibr" rid="bib89">Zhang et al., 2017</xref>). It is possible that <italic>H19</italic> functions vary from cell type to cell type (<xref ref-type="bibr" rid="bib67">Raveh et al., 2015</xref>). Alternatively, these functions might co-exist in a single cell but analyses to date have only looked at <italic>H19</italic> function from single perspectives and have missed its ability to perform in multiple pathways. To address this issue, we have begun to generate mutant <italic>H19</italic> alleles that disrupt specific functions. Here we show that <italic>H19ΔEx1/H19<sup>+</sup></italic> have 100× reduced levels of lncRNA but almost normal levels of <italic>Mir675-3p and -5</italic> p and still show cardiac pathology. Thus, the pathologies in LOI mice depend on the loss of <italic>H19</italic> lncRNA. To then address how the lncRNA might function, we generated mice carrying an <italic>H19</italic> allele missing <italic>Mirlet7</italic> binding sites. These mice show cardiac pathologies including extreme fibrosis. We find the fibrosis phenotype in <italic>H19ΔLet7</italic> mice to be especially interesting. We speculate that intensity relative to that seen in an <italic>H19</italic> null is most consistent with the idea that <italic>H19</italic> lncRNA has multiple roles in the cell and by disrupting only one role we have altered some balance, so that the animal is worse off than having no <italic>H19</italic> at all.</p><p>The strong phenotype in <italic>H19ΔLet7</italic> mice is consistent with several previous studies that emphasize the importance of <italic>H19</italic> lncRNA interactions with <italic>Mirlet7</italic> miRNAs but it is also paradoxical in that multiple studies of <italic>Mirlet7</italic> function in hearts indicate that <italic>Mirlet7</italic> functions as an anti-fibrotic factor. That is, reduced <italic>Mirlet7</italic> is a risk factor for fibrosis and fibrosis induces <italic>Mirlet7</italic>, presumably as a corrective measure (<xref ref-type="bibr" rid="bib2">Bao et al., 2013</xref>; <xref ref-type="bibr" rid="bib17">Elliot et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Sun et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Wang et al., 2015</xref>). The increased fibrosis in <italic>H19ΔLet7</italic> mice suggests that the simple model (that <italic>H19</italic> binds to and reduces <italic>Mirlet7</italic> bioavailability) is not correct or, more likely, that complex developmental interactions play critical roles that determine phenotypes in ways that are not yet understood. Either way, our results confirm the importance of animal models and the need for even more sophisticated conditional deletions.</p><p><italic>H19</italic> and <italic>Igf2</italic> are generally thought of as fetal genes since their expression is so strongly repressed after birth. This fact might suggest that the adult phenotypes in <italic>H19</italic>-deficient mice are downstream effects of the loss of <italic>H19</italic> in the developing heart. However, as already mentioned, at peak expression, <italic>H19</italic> levels are extraordinarily high. Thus, even after 100-fold developmentally regulated decrease, <italic>H19</italic> remains one of the top 100 genes in terms of RNA levels. For this reason, conditional ablation models will be needed to determine exactly when <italic>H19</italic> expression is important.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">H19</td><td align="left" valign="bottom">GeneBank</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://genome.ucsc.edu/cgi-bin/hgTracks?position=chr7:142575530-142578146&amp;hgsid=1131981893_fG5puyta3RVS2e6dVvALwBq8sP2D&amp;ncbiRefSeqCurated=pack&amp;ncbiRefSeqCurated_sel=1&amp;refSeqComposite_sel=1&amp;hgFind.matches=NR_130973.1,">NR_130973.1</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6 J (B6)</td><td align="left" valign="bottom">Jackson Labs</td><td align="left" valign="bottom">Jax: 000664</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6.FVB-Tg (Myh6-cre)2,182Mds/J</td><td align="left" valign="bottom">Jackson Labs</td><td align="left" valign="bottom">Jax: 011038</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain background (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">H19<sup>ΔICR</sup></td><td align="left" valign="bottom">Previous study from this lab</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10817754/">10817754</ext-link></td><td align="left" valign="bottom">Maintained by B6 backcross</td></tr><tr><td align="left" valign="bottom">Strain, strain background (mouse)</td><td align="left" valign="bottom">H19 BAC Transgene</td><td align="left" valign="bottom">Previous study from this lab</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10921905/">10921905</ext-link></td><td align="left" valign="bottom">Maintained by B6 backcross</td></tr><tr><td align="left" valign="bottom">Strain, strain background (mouse)</td><td align="left" valign="bottom">H19ΔEx1</td><td align="left" valign="bottom">Previous study from this lab</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/12270940/">12270940</ext-link></td><td align="left" valign="bottom">Maintained by B6 backcross</td></tr><tr><td align="left" valign="bottom">Strain, strain background (mouse)</td><td align="left" valign="bottom">H19ΔLet7</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">See Materials and methods</td><td align="left" valign="bottom">Maintained by B6 backcross</td></tr><tr><td align="left" valign="bottom">Cell line (Rattus norvegicucs)</td><td align="left" valign="bottom">H9c2 cells: Rat myocardium (embryo)</td><td align="left" valign="bottom">ATCC CRL-1446</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0286">CVCL_0286</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (vector control)</td><td align="left" valign="bottom">pcDNA3.1+</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">V790-20</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Primary myoblasts</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">See Materials and methods</td><td align="left" valign="bottom">Isolated from neonates</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Primary cardiac endothelial cells</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">See Materials and methods</td><td align="left" valign="bottom">Freshly isolated from neonates</td></tr><tr><td align="left" valign="bottom">Biological sample (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">Primary cardiomycytes</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">See Materials and methods</td><td align="left" valign="bottom">Freshly isolated from neonates</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref> for list of 23 primary and six secondary antibodies</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pcDNA3-H19</td><td align="left" valign="bottom">This study</td><td align="left" valign="bottom">Mouse EcoRI-SalI fragment cloned into Nhe-XhoI of pcDNA3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">See <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref> for list of oligonucleotides used for PCR</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Peptide, recombinant protein</td><td align="left" valign="bottom">Human Recombinant IGF2</td><td align="left" valign="bottom">Preprotech</td><td align="left" valign="bottom">Catalog # 100–12</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse IGF2 ELISA Kit</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab100696</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">H19 in situ probe</td><td align="left" valign="bottom">Advanced Cell Diagnostics</td><td align="left" valign="bottom">ACD 423751</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">H19 in situ probe</td><td align="left" valign="bottom">Advanced Cell Diagnostics</td><td align="left" valign="bottom">ACD 322360</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BMS 754807</td><td align="left" valign="bottom">Active Biochem</td><td align="left" valign="bottom">A-1013</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MEK1/2 Inhibitor PD98059</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">#9900</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">DESeq2</td><td align="left" valign="bottom"/><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015687">SCR_015687</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Bioconductor</td><td align="left" valign="bottom"/><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006442">SCR_006442</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Feature Counts</td><td align="left" valign="bottom"/><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_012919">SCR_012919</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Debian</td><td align="left" valign="bottom"/><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006638">SCR_006638</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">STAR</td><td align="left" valign="bottom"/><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_004463">SCR_004463</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animal studies</title><p>All mice were bred and housed in accordance with National Institutes of Health and United States Public Health Service policies. Animal research was performed only after protocols were approved by the National Institute of Child Health and Human Development Animal Care and Use Committee.</p><p><italic>H19<sup>ΔICR</sup>/H19<sup>+</sup></italic> (<xref ref-type="bibr" rid="bib73">Srivastava et al., 2000</xref>) and wild-type littermates or <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> (<xref ref-type="bibr" rid="bib74">Srivastava et al., 2003</xref>) and wild-type littermates were generated by backcrossing heterozygous females with C57BL/6 J males (Jackson Labs 000664). For tissue-specific LOI, we crossed <italic>H19<sup>ΔICR</sup>/H19<sup>ICRflox</sup></italic> females (<xref ref-type="bibr" rid="bib73">Srivastava et al., 2000</xref>) with males hemizygous for the <italic>Myh6-Cre</italic> transgene (Jackson Labs 011038) (<xref ref-type="bibr" rid="bib1">Agah et al., 1997</xref>). The H19 BAC transgene was generated as described (<xref ref-type="bibr" rid="bib38">Kaffer et al., 2001</xref>; <xref ref-type="bibr" rid="bib37">Kaffer et al., 2000</xref>) and used to generate <italic>H19<sup>ΔICR</sup>/H19<sup>+</sup> BAC</italic>+ females for backcrossing with C57BL/6 J males.</p><p>The <italic>H19ΔLet7</italic> allele was generated using CRISPR/Cas9 gene editing of RI mouse embryonic stem cells (ESCs). In step 1, we used gRNAs 5’-<named-content content-type="sequence">CACCGAGGGTTGCCAGTAAAGACTG</named-content>-3’ and 5’-<named-content content-type="sequence">CACCGCTGCCTCCAGGGAGGTGAT</named-content>-3’ to delete 25 bp (<named-content content-type="sequence">AGACTGAGGCCGCTGCCTCCAGGGAGGTGAT</named-content>) in exon 1. In step 2, we used gRNAs: 5’-<named-content content-type="sequence">CACCGCTTCTTGATTCAGAACGAGA</named-content>-3’ and 5’-<named-content content-type="sequence">CACCGACCACTACACTACCTGCCTC</named-content>-3’ to delete 48 bp (<named-content content-type="sequence">CGTTCTGAATCAAGAAGATGCTGCAATCAGAACCACTACACTACCTGC</named-content>) in exon 4. Positive clones were identified by PCR screens and then confirmed by sequencing 686 bp spanning the exon 1 deletion and 1086 bp spanning the exon four deletion. Founder mice were obtained by injecting mutated ESCs into C57BL/6 J blastocyts and then backcrossed twice with C57BL/6 J females.</p><p>Genotypes were determined by PCR analyses of gDNAs extracted from ear punch biopsies (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>).</p></sec><sec id="s4-2"><title>Electrocardiography measurements</title><p>Transthoracic echocardiography was performed using a high-frequency linear array ultrasound system (Vevo 2100, VisualSonics) and the MS-400 Transducer (VisualSonics) with a center operating frequency of 30 MHz, broadband frequency of 18–38 MHz, axial resolution of 50 mm, and footprint of 20 × 5 mm. M-mode images of the left ventricle were collected from the parasternal short-axis view at the midpapillary muscles at a 90° clockwise rotation of the imaging probe from the parasternal long-axis view. Form the M-mode images, the left ventricle systolic and diastolic posterior and anterior wall thicknesses and end-systolic and -diastolic internal left ventricle chamber dimensions were measured using the leading-edge method. Left ventricular functional values of fractional shortening and ejection fraction were calculated from the wall thicknesses and chamber dimension measurements using system software. Mice were imaged in the supine position while placed on heated platform after light anesthesia using isoflurane delivered by nose cone.</p></sec><sec id="s4-3"><title>Blood pressure measurements</title><p>After sedation with isoflurane, a pressure catheter (1.0-Fr, model SPR1000, Millar Instruments, Houston, TX) was inserted into the right carotid and advanced to the ascending aorta. After 5 min acclimation, pressures were recorded using Chart 5 software (AD Instruments, Colorado Springs, CO) (<xref ref-type="bibr" rid="bib45">Knutsen et al., 2018</xref>).</p></sec><sec id="s4-4"><title>Arterial pressure-diameter testing</title><p>Ascending aortas (from the root to just distal to the innominate branch point) and left carotid arteries (from the transverse aorta to 6 mm up the common carotid) were dissected and mounted on a pressure arteriograph (Danish Myotechnology, Copenhagen, Denmark) in balanced physiological saline (130 mM NaCl, 4.7 mM KCl, 1.6 mM CaCl<sub>2</sub>, 1.18 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, 1.17 mM KH<sub>2</sub>PO<sub>4</sub>, 14.8 mM NaHCO<sub>3</sub>, 5.5 mM dextrose, and 0.026 mM EDTA, pH 7.4) at 37 °C. Vessels were transilluminated under a microscope connected to a charge-coupled device camera and computerized measurement system (Myoview, Danish Myotechnology) to allow continuous recording of vessel diameters. Prior to data capture vessels were pressurized and stretched to in vivo length (<xref ref-type="bibr" rid="bib81">Wagenseil et al., 2005</xref>). Intravascular pressure was increased from 0 to 175 mmHg in 25 mmHg steps. At each step, the outer diameter (OD) of the vessel was measured and manually recorded. Segmental distensibility was calculated from the pressure diameter curves as follows: distensibility (SD<sub>25</sub>) over a 25 mmHg interval = [OD<sub>Higher Pressure (H)</sub> − OD<sub>Lower Pressure(L)</sub>]/OD<sub>(L)</sub>/25 (<xref ref-type="bibr" rid="bib45">Knutsen et al., 2018</xref>).</p></sec><sec id="s4-5"><title>Histological analyses</title><p>Hearts from adult mice were fixed by Langendorff perfusion or by transcardiac perfusion using 4 % paraformaldehyde (PFA) and embedded in paraffin. Fetal and neonatal hearts were isolated and then fixed by submersion in 4 % PFA before embedding. From embedded hearts, we obtained 5 mm transverse sections for analysis. Masson’s Trichrome (Sigma Aldrich, HT15, St. Louis Missouri) and Picosirius Red (Sigma Aldrich, 365548) staining were according to supplier’s instructions. Fiber diameter index was quantitated using Hamamatsu-NDP software.</p></sec><sec id="s4-6"><title>Immunofluorescence and immunohistochemistry</title><p>Primary myocytes and H19C2 cells were fixed with 4% PFA, permeabilized with 0.5% Triton, and blocked with 10% normal serum before incubation with antibodies. Paraffin sections were deparaffinized and rehydrated according to standard protocols. Antigen retrieval was applied using citrate buffer (Abcam, 1b93679, Cambridge, MA) for 20 min and then maintained at a sub-boiling temperature for 10 min. Sections were treated with serum-free blocking solution (DAKO, X0909, Santa Clara, CA) and all antibodies (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) diluted in antibody diluent solution (DAKO, S0809). Secondary staining was performed for 30 min at RT. Samples were imaged with a Carl Zeiss 880 laser scanning microscope using a 40× oil immersion objective. Images were composed and edited in ZEN&amp;LSM image software provided by Carl Zeiss or Illustrator 6.0 (Adobe).</p></sec><sec id="s4-7"><title>RNA in situ hybridization</title><p>Single color probes for H19 were purchased from Advanced Cell Diagnostics (ACD 423751, Newark, CA). RNA in-situ hybridization was performed on paraffin sections using the 2.5 HD Brown Detection Kit (ACD 322310). For dual staining with antibodies, we used H19-RD chromagen kit (ACD 322360).</p></sec><sec id="s4-8"><title>Immunoblotting</title><p>Cell extracts and tissue extracts were prepared using M-PER mammalian protein extraction buffer (Thermo Fisher 78501, Waltham, MA) or T-PER tissue protein extraction buffer (Thermo Fisher 78510), respectively. Protein concentrations were assayed using a BCA Protein Assay Kit (Pierce 23227, Waltham, MA). Proteins were fractionated by electrophoresis on 12% or on 4%–20% SDS−PAGE gels and then transferred to nitrocellulose. Antibodies (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) were diluted in antibody enhancer buffer (Pierce 46644).</p></sec><sec id="s4-9"><title>Cell culture</title><p>Primary cardiomyocytes were isolated form P1 pups using the Pierce Primary Cardiomyocyte Isolation Kit (Thermo Fisher 88281). H19c2 (<xref ref-type="bibr" rid="bib5">Branco et al., 2015</xref>) cells were purchased from ATCC (CXRL-1446). Cells were grown at 37°C in 5% CO<sub>2</sub> in DMEM + 10% FBS. Cardiomyocyte identity was confirmed by cell morphology and by immunohistochemistry for cardiomyoyte-specific markers including Myh6. Cell surface index was quantitated using Carl Zeiss-LSM software (n = 50 for each of three independent experiments).</p><p>To prepare primary endothelial cells, neonatal hearts were isolated and dissociated into single cells using Miltenyi Biotec Neonatal Heart Dissociation Kit (130-098-373, Gaithersburg, MD) but omitting the Red Cell Lysis step. Endothelial cells were purified based on CD31 expression (Miltenyi Biotec Neonatal Cardiac Endothelial Cell Isolation Kit, 130-104-183).</p><p>Primary myoblasts were generated and grown as described (<xref ref-type="bibr" rid="bib63">Park et al., 2017</xref>). Cell identify is confirmed by expression of myoblast-specific markers (including MyoG), and by determining that upon serum depletion, &gt;90% cells will differentate into elongated, multinucleate myotubes.</p><p>Cells are negative for mycoplasma contamination.</p></sec><sec id="s4-10"><title>Quantitative real-time PCR for RNA samples</title><p>Conventional RNAs were prepared from three to five independent biological samples, analyzed using a Thermo Fisher NANODROP 2000c to evaluate purity and yield, and then stored at –70°C. cDNA samples were prepared with and without reverse transcriptase using oligo-dT primers (Roche, 04 887 352 001). cDNAs were analyzed using SYBR Green (Roche, 04 887 352 001) on the Roche Light Cycler 480 II (45 cycles with annealing at 60°C) using primers described in <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>. For each primer pair, we established standard curves to evaluate slope, y-intercepts, and PCR efficiency and to determine the dynamic range of the assay. Assay specificity was determined by melting point analyses and gel electrophoresis.</p><p>For microRNA analyses, we used mirVanaTM miRNA Isolation Kit and TaqMan MicroRNA Assays Thermo Fisher, 4437975; Assay ID 001973 (U6), 001940 (Mir675-5p), 001941 (Mir675-3p).</p></sec><sec id="s4-11"><title>RNA pull-down</title><p>Primary myoblast cell cultures were generated and grown as described (<xref ref-type="bibr" rid="bib63">Park et al., 2017</xref>). Cell RNA pull-down assay was performed essentially as previously described (<xref ref-type="bibr" rid="bib46">Lee et al., 2020</xref>). Briefly, cells were fixed for 10 minutes at room temperature with 2.5% formaldehyde in PBS before quenching with 0.125 M glycine for 5 min. Cells were rinsed, resuspended in NET-2 buffer (50  mM Tris–HCl, pH 7.4, 150–300  mM NaCl, 0.05% NP-40, 0.05% deoxycholic acid, 1 mM PMSF, 2 mM benzamidine), and sonicated. Cell lysates were incubated with biotin-labeled probes synthesized by Eurofins Genomics and then pulled down with streptavidin beads (Sigma-Aldrich). Precipitated RNA and miRNA were subsequently subjected to RT-qPCR. The sequences of biotin-labeled h19 probes used in this study were as follows: <named-content content-type="sequence">CTCAGTCTTTACTGGCAACC</named-content>-BIOTIN, <named-content content-type="sequence">TGTAAAATCCCTCTGGAGTC</named-content>-BIOTIN, <named-content content-type="sequence">CTCCCTAGAAACTCATTCAT</named-content>-BIOTIN, <named-content content-type="sequence">CTTCGAGACACCGATCACTG</named-content>-BIOTIN, <named-content content-type="sequence">ATGTCATGTCTTTCTGTCAC</named-content>-BIOTIN, <named-content content-type="sequence">TTGACACCATCTGTTCTTTC</named-content>-BIOTIN, <named-content content-type="sequence">AAGAGGTTTACACACTCGCT</named-content>-BIOTIN. The sequence of biotin-labeled control probe was <named-content content-type="sequence">CCTACGCCACCAATTTCGT</named-content>-BIOTIN.</p></sec><sec id="s4-12"><title>ELISA</title><p>IGF2 secreted peptide was assayed with the Mouse IGF2 ELISA KIT (Abcam, ab100696) on 10 independent samples.</p></sec><sec id="s4-13"><title>RNA sequencing and analyses</title><p>For analyses in adult animals, RNAs were isolated from 6 month <italic>H19<sup>ΔICR</sup>/H19<sup>ΔICR</sup></italic> and <italic>H19+/H19+</italic> littermates (two per genotype) using RNeasy Plus Mini Kit (Qiagen). Samples with RNA Integrity numbers &gt; 9 were Ribosomal RNA depleted using RiboZero Gold Kit (Illumina). Libraries were prepared using an RNA Sample Prep V2 Kit (Illumina) and sequenced (Illumina HiSeq2500) to generate paired-end 101 bp reads that were aligned to the mouse genome version mm10 using STAR v2.5.3a (<xref ref-type="bibr" rid="bib13">Dobin et al., 2013</xref>). Differential expression analyses were performed using DESeq2 (<xref ref-type="bibr" rid="bib52">Love et al., 2014</xref>).</p><p>For analyses in neonates, RNAs were isolated from purified cardiac endothelial cells isolated from <italic>H19<sup>ΔEx1</sup>/H19<sup>+</sup></italic> (N = 3) and <italic>H19<sup>+</sup>/H19<sup>+</sup></italic> (N = 4) littermates. Libraries were generated from samples with RNA Integrity Numbers &gt; 9 and were sequenced and analyzed as described above.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>None</p></fn><fn fn-type="COI-statement" id="conf2"><p>none</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Methodology, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Software, Visualization, Writing – original draft</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Methodology, Visualization</p></fn><fn fn-type="con" id="con7"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Investigation, Supervision, Visualization, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Investigation, Supervision, Writing - review and editing</p></fn><fn fn-type="con" id="con10"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Supervision, Validation, Writing - review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Formal analysis, Funding acquisition, Investigation, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animals were handled according to approved institutional animal care and use committee (IACUC) protocols (050 and 063) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Surgery was performed under Avertin anesthesia and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Correlations between echocardiography phenotypes in 13 month old mice.</title><p>As described in the text, each mouse presents a unique array of phenotypes. LV, left ventricular; AW, anterior wall; OT, outflow tract; sys, systole; dia, diastole.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Primers used for qRT-PCR and for genotyping.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Antibodies used in this study.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67250-supp3-v2.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-67250-transrepform1-v2.pdf"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Sequencing data are deposited in the NCBI Gene Expression Omnibus (GEO) under series accession number GSE111418.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Springer</surname><given-names>D</given-names></name><name><surname>Rahat</surname><given-names>B</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Mis-expression of Igf2 and H19 work independently on distinct cell types to cause cardiomyopathy in a Beckwtih Wiedemann mouse model</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111418">GSE111418</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Victoria Biggs and Jeanne Yimdjo for animal husbandry. This work was supported by the Division of Intramural Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agah</surname><given-names>R</given-names></name><name><surname>Frenkel</surname><given-names>PA</given-names></name><name><surname>French</surname><given-names>BA</given-names></name><name><surname>Michael</surname><given-names>LH</given-names></name><name><surname>Overbeek</surname><given-names>PA</given-names></name><name><surname>Schneider</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Gene recombination in postmitotic cells Targeted expression of CRE recombinase provokes cardiac-restricted, site-specific rearrangement in adult ventricular muscle in vivo</article-title><source>The Journal of Clinical Investigation</source><volume>100</volume><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1172/JCI119509</pub-id><pub-id pub-id-type="pmid">9202069</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>MH</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>YW</given-names></name><name><surname>Lou</surname><given-names>XY</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells</article-title><source>International Journal of Molecular Sciences</source><volume>14</volume><fpage>23086</fpage><lpage>23102</lpage><pub-id pub-id-type="doi">10.3390/ijms141123086</pub-id><pub-id pub-id-type="pmid">24284400</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barlow</surname><given-names>DP</given-names></name><name><surname>Bartolomei</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genomic imprinting in mammals</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>6</volume><elocation-id>a018382</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a018382</pub-id><pub-id pub-id-type="pmid">24492710</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>D</given-names></name><name><surname>Halje</surname><given-names>M</given-names></name><name><surname>Nordin</surname><given-names>M</given-names></name><name><surname>Engström</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Insulin-like growth factor 2 in development and disease: A mini-review</article-title><source>Gerontology</source><volume>59</volume><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1159/000343995</pub-id><pub-id pub-id-type="pmid">23257688</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Branco</surname><given-names>AF</given-names></name><name><surname>Pereira</surname><given-names>SP</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Gusev</surname><given-names>O</given-names></name><name><surname>Rizvanov</surname><given-names>AA</given-names></name><name><surname>Oliveira</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Gene expression profiling of h9c2 myoblast differentiation towards a cardiac-like phenotype</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0129303</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0129303</pub-id><pub-id pub-id-type="pmid">26121149</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brannan</surname><given-names>CI</given-names></name><name><surname>Dees</surname><given-names>EC</given-names></name><name><surname>Ingram</surname><given-names>RS</given-names></name><name><surname>Tilghman</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>The product of the h19 gene may function as an RNA</article-title><source>Molecular and Cellular Biology</source><volume>10</volume><fpage>28</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1128/mcb.10.1.28-36.1990</pub-id><pub-id pub-id-type="pmid">1688465</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Cullen</surname><given-names>BR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The imprinted h19 noncoding RNA is a primary microrna precursor</article-title><source>RNA</source><volume>13</volume><fpage>313</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1261/rna.351707</pub-id><pub-id pub-id-type="pmid">17237358</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carboni</surname><given-names>JM</given-names></name><name><surname>Wittman</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>F</given-names></name><name><surname>Greer</surname><given-names>A</given-names></name><name><surname>Hurlburt</surname><given-names>W</given-names></name><name><surname>Hillerman</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>C</given-names></name><name><surname>Cantor</surname><given-names>GH</given-names></name><name><surname>Dell-John</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Discenza</surname><given-names>L</given-names></name><name><surname>Menard</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Trainor</surname><given-names>G</given-names></name><name><surname>Vyas</surname><given-names>D</given-names></name><name><surname>Kramer</surname><given-names>R</given-names></name><name><surname>Attar</surname><given-names>RM</given-names></name><name><surname>Gottardis</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR</article-title><source>Molecular Cancer Therapeutics</source><volume>8</volume><fpage>3341</fpage><lpage>3349</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0499</pub-id><pub-id pub-id-type="pmid">19996272</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>MM</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2005">2005</year><article-title>Beckwith-wiedemann syndrome: Historical, clinicopathological, and etiopathogenetic perspectives</article-title><source>Pediatric and Developmental Pathology</source><volume>8</volume><fpage>287</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1007/s10024-005-1154-9</pub-id><pub-id pub-id-type="pmid">16010495</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBaun</surname><given-names>MR</given-names></name><name><surname>Niemitz</surname><given-names>EL</given-names></name><name><surname>Feinberg</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Association of in vitro fertilization with Beckwith-wiedemann syndrome and epigenetic alterations of lit1 and h19</article-title><source>American Journal of Human Genetics</source><volume>72</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1086/346031</pub-id><pub-id pub-id-type="pmid">12439823</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Descartes</surname><given-names>M</given-names></name><name><surname>Romp</surname><given-names>R</given-names></name><name><surname>Franklin</surname><given-names>J</given-names></name><name><surname>Biggio</surname><given-names>JR</given-names></name><name><surname>Zehnbauer</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Constitutional H19 hypermethylation in a patient with isolated cardiac tumor</article-title><source>American Journal of Medical Genetics. Part A</source><volume>146A</volume><fpage>2126</fpage><lpage>2129</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.32421</pub-id><pub-id pub-id-type="pmid">18627058</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>BK</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name><name><surname>Dutta</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>491</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1101/gad.234419.113</pub-id><pub-id pub-id-type="pmid">24532688</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Star: Ultrafast Universal RNA-SEQ aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doornbos</surname><given-names>ME</given-names></name><name><surname>Maas</surname><given-names>SM</given-names></name><name><surname>McDonnell</surname><given-names>J</given-names></name><name><surname>Vermeiden</surname><given-names>JPW</given-names></name><name><surname>Hennekam</surname><given-names>RCM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Infertility, assisted reproduction technologies and imprinting disturbances: a Dutch study</article-title><source>Human Reproduction</source><volume>22</volume><fpage>2476</fpage><lpage>2480</lpage><pub-id pub-id-type="doi">10.1093/humrep/dem172</pub-id><pub-id pub-id-type="pmid">17586835</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drut</surname><given-names>R</given-names></name><name><surname>Quijano</surname><given-names>G</given-names></name><name><surname>Altamirano</surname><given-names>ME</given-names></name><name><surname>Jones</surname><given-names>MC</given-names></name><name><surname>Maffessoli</surname><given-names>OB</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Vascular malformation and choroid plexus adrenal heterotopia: New findings in Beckwith-wiedemann syndrome?</article-title><source>Fetal and Pediatric Pathology</source><volume>25</volume><fpage>191</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1080/15513810601015704</pub-id><pub-id pub-id-type="pmid">17162526</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eggermann</surname><given-names>T</given-names></name><name><surname>Perez de Nanclares</surname><given-names>G</given-names></name><name><surname>Maher</surname><given-names>ER</given-names></name><name><surname>Temple</surname><given-names>IK</given-names></name><name><surname>Tümer</surname><given-names>Z</given-names></name><name><surname>Monk</surname><given-names>D</given-names></name><name><surname>Mackay</surname><given-names>DJG</given-names></name><name><surname>Grønskov</surname><given-names>K</given-names></name><name><surname>Riccio</surname><given-names>A</given-names></name><name><surname>Linglart</surname><given-names>A</given-names></name><name><surname>Netchine</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Imprinting disorders: A group of congenital disorders with overlapping patterns of molecular changes affecting imprinted loci</article-title><source>Clinical Epigenetics</source><volume>7</volume><elocation-id>123</elocation-id><pub-id pub-id-type="doi">10.1186/s13148-015-0143-8</pub-id><pub-id pub-id-type="pmid">26583054</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliot</surname><given-names>S</given-names></name><name><surname>Periera-Simon</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>X</given-names></name><name><surname>Catanuto</surname><given-names>P</given-names></name><name><surname>Rubio</surname><given-names>G</given-names></name><name><surname>Shahzeidi</surname><given-names>S</given-names></name><name><surname>El Salem</surname><given-names>F</given-names></name><name><surname>Shapiro</surname><given-names>J</given-names></name><name><surname>Briegel</surname><given-names>K</given-names></name><name><surname>Korach</surname><given-names>KS</given-names></name><name><surname>Glassberg</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MICRORNA let-7 downregulates ligand-independent estrogen receptor-mediated male-predominant pulmonary fibrosis</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>200</volume><fpage>1246</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1164/rccm.201903-0508OC</pub-id><pub-id pub-id-type="pmid">31291549</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>M</given-names></name><name><surname>Bayly</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>T</given-names></name><name><surname>Temple</surname><given-names>IK</given-names></name><name><surname>Maher</surname><given-names>ER</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Clinical features and natural history of Beckwith-wiedemann syndrome: Presentation of 74 new cases</article-title><source>Clinical Genetics</source><volume>46</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1111/j.1399-0004.1994.tb04219.x</pub-id><pub-id pub-id-type="pmid">7820926</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evrard</surname><given-names>SM</given-names></name><name><surname>Lecce</surname><given-names>L</given-names></name><name><surname>Michelis</surname><given-names>KC</given-names></name><name><surname>Nomura-Kitabayashi</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>G</given-names></name><name><surname>Purushothaman</surname><given-names>KR</given-names></name><name><surname>d’Escamard</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>JR</given-names></name><name><surname>Hadri</surname><given-names>L</given-names></name><name><surname>Fujitani</surname><given-names>K</given-names></name><name><surname>Moreno</surname><given-names>PR</given-names></name><name><surname>Benard</surname><given-names>L</given-names></name><name><surname>Rimmele</surname><given-names>P</given-names></name><name><surname>Cohain</surname><given-names>A</given-names></name><name><surname>Mecham</surname><given-names>B</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>Nabel</surname><given-names>EG</given-names></name><name><surname>Hajjar</surname><given-names>R</given-names></name><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Boehm</surname><given-names>M</given-names></name><name><surname>Kovacic</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>11853</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms11853</pub-id><pub-id pub-id-type="pmid">27340017</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>AP</given-names></name><name><surname>Tycko</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The history of cancer epigenetics</article-title><source>Nature Reviews. Cancer</source><volume>4</volume><fpage>143</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/nrc1279</pub-id><pub-id pub-id-type="pmid">14732866</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabory</surname><given-names>A</given-names></name><name><surname>Jammes</surname><given-names>H</given-names></name><name><surname>Dandolo</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The H19 locus: Role of an imprinted non-coding RNA in growth and development</article-title><source>BioEssays</source><volume>32</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1002/bies.200900170</pub-id><pub-id pub-id-type="pmid">20486133</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Jurczak</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>XB</given-names></name><name><surname>Dandolo</surname><given-names>L</given-names></name><name><surname>Szendroedi</surname><given-names>J</given-names></name><name><surname>Roden</surname><given-names>M</given-names></name><name><surname>Flannery</surname><given-names>C</given-names></name><name><surname>Taylor</surname><given-names>H</given-names></name><name><surname>Carmichael</surname><given-names>GG</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The H19/let-7 double-negative feedback loop contributes to glucose metabolism in muscle cells</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>13799</fpage><lpage>13811</lpage><pub-id pub-id-type="doi">10.1093/nar/gku1160</pub-id><pub-id pub-id-type="pmid">25399420</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Chu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Microarray analysis of differential gene expression profile between human fetal and adult heart</article-title><source>Pediatric Cardiology</source><volume>38</volume><fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1007/s00246-017-1569-x</pub-id><pub-id pub-id-type="pmid">28331934</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>H</given-names></name><name><surname>Bu</surname><given-names>HF</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name><name><surname>Chou</surname><given-names>PM</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Bartolomei</surname><given-names>MS</given-names></name><name><surname>De Plaen</surname><given-names>IG</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Tan</surname><given-names>XD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>In Inflamed Intestinal Tissues and Epithelial Cells, Interleukin 22 Signaling Increases Expression of H19 Long Noncoding RNA, Which Promotes Mucosal Regeneration</article-title><source>Gastroenterology</source><volume>155</volume><fpage>144</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2018.03.058</pub-id><pub-id pub-id-type="pmid">29621481</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gicquel</surname><given-names>C</given-names></name><name><surname>Gaston</surname><given-names>V</given-names></name><name><surname>Mandelbaum</surname><given-names>J</given-names></name><name><surname>Siffroi</surname><given-names>JP</given-names></name><name><surname>Flahault</surname><given-names>A</given-names></name><name><surname>Le Bouc</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>In vitro fertilization may increase the risk of Beckwith-wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene</article-title><source>American Journal of Human Genetics</source><volume>72</volume><fpage>1338</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1086/374824</pub-id><pub-id pub-id-type="pmid">12772698</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goumans</surname><given-names>MJ</given-names></name><name><surname>van Zonneveld</surname><given-names>AJ</given-names></name><name><surname>ten Dijke</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Transforming growth factor beta-induced endothelial-to-mesenchymal transition: A switch to cardiac fibrosis?</article-title><source>Trends in Cardiovascular Medicine</source><volume>18</volume><fpage>293</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2009.01.001</pub-id><pub-id pub-id-type="pmid">19345316</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>RD</given-names></name><name><surname>Somer</surname><given-names>A</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Craenen</surname><given-names>J</given-names></name><name><surname>Nadas</surname><given-names>AS</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Cardiovascular abnormalities in the Beckwith-wiedemann syndrome</article-title><source>American Journal of Diseases of Children</source><volume>131</volume><fpage>293</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1001/archpedi.1977.02120160047007</pub-id><pub-id pub-id-type="pmid">842515</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadji</surname><given-names>F</given-names></name><name><surname>Boulanger</surname><given-names>MC</given-names></name><name><surname>Guay</surname><given-names>SP</given-names></name><name><surname>Gaudreault</surname><given-names>N</given-names></name><name><surname>Amellah</surname><given-names>S</given-names></name><name><surname>Mkannez</surname><given-names>G</given-names></name><name><surname>Bouchareb</surname><given-names>R</given-names></name><name><surname>Marchand</surname><given-names>JT</given-names></name><name><surname>Nsaibia</surname><given-names>MJ</given-names></name><name><surname>Guauque-Olarte</surname><given-names>S</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>Bouchard</surname><given-names>L</given-names></name><name><surname>Bossé</surname><given-names>Y</given-names></name><name><surname>Mathieu</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Altered DNA methylation of long noncoding RNA h19 in calcific aortic valve disease promotes mineralization by silencing notch1</article-title><source>Circulation</source><volume>134</volume><fpage>1848</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.116.023116</pub-id><pub-id pub-id-type="pmid">27789555</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>J</given-names></name><name><surname>Oke</surname><given-names>K</given-names></name><name><surname>Breheny</surname><given-names>S</given-names></name><name><surname>Algar</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Beckwith-Wiedemann syndrome and IVF: a case-control study</article-title><source>American Journal of Human Genetics</source><volume>75</volume><fpage>526</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1086/423902</pub-id><pub-id pub-id-type="pmid">15284956</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>H</given-names></name><name><surname>Hiura</surname><given-names>H</given-names></name><name><surname>Kitamura</surname><given-names>A</given-names></name><name><surname>Miyauchi</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Okae</surname><given-names>H</given-names></name><name><surname>Kyono</surname><given-names>K</given-names></name><name><surname>Kagami</surname><given-names>M</given-names></name><name><surname>Ogata</surname><given-names>T</given-names></name><name><surname>Arima</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Association of four imprinting disorders and ART</article-title><source>Clinical Epigenetics</source><volume>11</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1186/s13148-019-0623-3</pub-id><pub-id pub-id-type="pmid">30732658</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinzel</surname><given-names>FR</given-names></name><name><surname>Hohendanner</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Sedej</surname><given-names>S</given-names></name><name><surname>Edelmann</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Myocardial hypertrophy and its role in heart failure with preserved ejection fraction</article-title><source>Journal of Applied Physiology</source><volume>119</volume><fpage>1233</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00374.2015</pub-id><pub-id pub-id-type="pmid">26183480</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsthemke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>In brief: Genomic imprinting and imprinting diseases</article-title><source>The Journal of Pathology</source><volume>232</volume><fpage>485</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1002/path.4326</pub-id><pub-id pub-id-type="pmid">24395592</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ideraabdullah</surname><given-names>FY</given-names></name><name><surname>Vigneau</surname><given-names>S</given-names></name><name><surname>Bartolomei</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Genomic imprinting mechanisms in mammals</article-title><source>Mutation Research</source><volume>647</volume><fpage>77</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2008.08.008</pub-id><pub-id pub-id-type="pmid">18778719</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacob</surname><given-names>KJ</given-names></name><name><surname>Robinson</surname><given-names>WP</given-names></name><name><surname>Lefebvre</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Beckwith-wiedemann and Silver-russell syndromes: Opposite developmental imbalances in imprinted regulators of placental function and embryonic growth</article-title><source>Clinical Genetics</source><volume>84</volume><fpage>326</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1111/cge.12143</pub-id><pub-id pub-id-type="pmid">23495910</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Increased level of H19 long noncoding RNA promotes invasion, angiogenesis, and stemness of glioblastoma cells</article-title><source>Journal of Neurosurgery</source><volume>2016</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.3171/2014.12.JNS1426.test</pub-id><pub-id pub-id-type="pmid">28306408</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JP</given-names></name><name><surname>Beischel</surname><given-names>L</given-names></name><name><surname>Schwanke</surname><given-names>C</given-names></name><name><surname>Styren</surname><given-names>K</given-names></name><name><surname>Crunk</surname><given-names>A</given-names></name><name><surname>Schoof</surname><given-names>J</given-names></name><name><surname>Elias</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Overrepresentation of pregnancies conceived by artificial reproductive technology in prenatally identified fetuses with Beckwith-Wiedemann syndrome</article-title><source>Journal of Assisted Reproduction and Genetics</source><volume>35</volume><fpage>985</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1007/s10815-018-1228-z</pub-id><pub-id pub-id-type="pmid">29936652</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaffer</surname><given-names>CR</given-names></name><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>KY</given-names></name><name><surname>Ives</surname><given-names>E</given-names></name><name><surname>Hsieh</surname><given-names>S</given-names></name><name><surname>Batlle</surname><given-names>J</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>SP</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A transcriptional insulator at the imprinted H19/Igf2 locus</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>1908</fpage><lpage>1919</lpage></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaffer</surname><given-names>CR</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regulatory mechanisms at the mouse Igf2/H19 locus</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>8189</fpage><lpage>8196</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.23.8189-8196.2001</pub-id><pub-id pub-id-type="pmid">11689707</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalish</surname><given-names>JM</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Bartolomei</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epigenetics and imprinting in human disease</article-title><source>The International Journal of Developmental Biology</source><volume>58</volume><fpage>291</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1387/ijdb.140077mb</pub-id><pub-id pub-id-type="pmid">25023695</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallen</surname><given-names>AN</given-names></name><name><surname>Zhou</surname><given-names>XB</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Qiao</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Yi</surname><given-names>JS</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Min</surname><given-names>W</given-names></name><name><surname>Bennett</surname><given-names>AM</given-names></name><name><surname>Gregory</surname><given-names>RI</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The imprinted H19 lncRNA antagonizes let-7 microRNAs</article-title><source>Molecular Cell</source><volume>52</volume><fpage>101</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.08.027</pub-id><pub-id pub-id-type="pmid">24055342</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keniry</surname><given-names>A</given-names></name><name><surname>Oxley</surname><given-names>D</given-names></name><name><surname>Monnier</surname><given-names>P</given-names></name><name><surname>Kyba</surname><given-names>M</given-names></name><name><surname>Dandolo</surname><given-names>L</given-names></name><name><surname>Smits</surname><given-names>G</given-names></name><name><surname>Reik</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The H19 lincrna is a developmental reservoir of mir-675 that suppresses growth and igf1r</article-title><source>Nature Cell Biology</source><volume>14</volume><fpage>659</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/ncb2521</pub-id><pub-id pub-id-type="pmid">22684254</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DK</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name><name><surname>Pratt</surname><given-names>RE</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>H19, a developmentally regulated gene, is reexpressed in rat vascular smooth muscle cells after injury</article-title><source>The Journal of Clinical Investigation</source><volume>93</volume><fpage>355</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1172/JCI116967</pub-id><pub-id pub-id-type="pmid">8282806</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kisanuki</surname><given-names>YY</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Miyazaki</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>SC</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Tie2-cre transgenic mice: A new model for endothelial cell-lineage analysis in vivo</article-title><source>Developmental Biology</source><volume>230</volume><fpage>230</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1006/dbio.2000.0106</pub-id><pub-id pub-id-type="pmid">11161575</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knopp</surname><given-names>C</given-names></name><name><surname>Rudnik-Schöneborn</surname><given-names>S</given-names></name><name><surname>Zerres</surname><given-names>K</given-names></name><name><surname>Gencik</surname><given-names>M</given-names></name><name><surname>Spengler</surname><given-names>S</given-names></name><name><surname>Eggermann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>twenty-one years to the right diagnosis - clinical overlap of Simpson-Golabi-Behmel and Beckwith-Wiedemann syndrome</article-title><source>American Journal of Medical Genetics. Part A</source><volume>167A</volume><fpage>151</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.36825</pub-id><pub-id pub-id-type="pmid">25339544</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knutsen</surname><given-names>RH</given-names></name><name><surname>Beeman</surname><given-names>SC</given-names></name><name><surname>Broekelmann</surname><given-names>TJ</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Tsang</surname><given-names>KM</given-names></name><name><surname>Kovacs</surname><given-names>A</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Danback</surname><given-names>JR</given-names></name><name><surname>Watson</surname><given-names>A</given-names></name><name><surname>Wardlaw</surname><given-names>A</given-names></name><name><surname>Wagenseil</surname><given-names>JE</given-names></name><name><surname>Garbow</surname><given-names>JR</given-names></name><name><surname>Shoykhet</surname><given-names>M</given-names></name><name><surname>Kozel</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Minoxidil improves vascular compliance, restores cerebral blood flow, and alters extracellular matrix gene expression in a model of chronic vascular stiffness</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>315</volume><fpage>H18</fpage><lpage>H32</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00683.2017</pub-id><pub-id pub-id-type="pmid">29498532</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HC</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Hwang</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>SB</given-names></name><name><surname>You</surname><given-names>JS</given-names></name><name><surname>Min</surname><given-names>BS</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Ko</surname><given-names>YG</given-names></name><name><surname>Gorospe</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A novel long noncoding RNA Linc-ASEN represses cellular senescence through multileveled reduction of p21 expression</article-title><source>Cell Death and Differentiation</source><volume>27</volume><fpage>1844</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1038/s41418-019-0467-6</pub-id><pub-id pub-id-type="pmid">31819156</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Cavallero</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>THP</given-names></name><name><surname>Hughes</surname><given-names>J</given-names></name><name><surname>Hassan</surname><given-names>AB</given-names></name><name><surname>Brüning</surname><given-names>JC</given-names></name><name><surname>Pashmforoush</surname><given-names>M</given-names></name><name><surname>Sucov</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development</article-title><source>Development</source><volume>138</volume><fpage>1795</fpage><lpage>1805</lpage><pub-id pub-id-type="doi">10.1242/dev.054338</pub-id><pub-id pub-id-type="pmid">21429986</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SG</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rapamycin: one drug, many effects</article-title><source>Cell Metabolism</source><volume>19</volume><fpage>373</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.01.001</pub-id><pub-id pub-id-type="pmid">24508508</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Lei</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>H19 derived microRNA-675 regulates cell proliferation and migration through CDK6 in glioma</article-title><source>American Journal of Translational Research</source><volume>7</volume><fpage>1747</fpage><lpage>1764</lpage></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Lei</surname><given-names>CG</given-names></name><name><surname>Wang</surname><given-names>ZC</given-names></name><name><surname>Shi</surname><given-names>GJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>LNCRNA H19 promotes the development of hepatitis b related hepatocellular carcinoma through regulating microrna-22 via EMT pathway</article-title><source>European Review for Medical and Pharmacological Sciences</source><volume>23</volume><fpage>5392</fpage><lpage>5401</lpage><pub-id pub-id-type="doi">10.26355/eurrev_201906_18208</pub-id><pub-id pub-id-type="pmid">31298392</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longardt</surname><given-names>AC</given-names></name><name><surname>Nonnenmacher</surname><given-names>A</given-names></name><name><surname>Graul-Neumann</surname><given-names>L</given-names></name><name><surname>Opgen-Rhein</surname><given-names>B</given-names></name><name><surname>Henrich</surname><given-names>W</given-names></name><name><surname>Bührer</surname><given-names>C</given-names></name><name><surname>Hüseman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Fetal intracardiac rhabdomyoma in Beckwith-wiedemann syndrome</article-title><source>Journal of Clinical Ultrasound</source><volume>42</volume><fpage>569</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1002/jcu.22164</pub-id><pub-id pub-id-type="pmid">24752985</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Nong</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Yuan</surname><given-names>Z</given-names></name><name><surname>Ai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT</article-title><source>Tumour Biology</source><volume>35</volume><fpage>9163</fpage><lpage>9169</lpage><pub-id pub-id-type="doi">10.1007/s13277-014-2185-5</pub-id><pub-id pub-id-type="pmid">24920070</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>ER</given-names></name><name><surname>Brueton</surname><given-names>LA</given-names></name><name><surname>Bowdin</surname><given-names>SC</given-names></name><name><surname>Luharia</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>W</given-names></name><name><surname>Cole</surname><given-names>TR</given-names></name><name><surname>Macdonald</surname><given-names>F</given-names></name><name><surname>Sampson</surname><given-names>JR</given-names></name><name><surname>Barratt</surname><given-names>CL</given-names></name><name><surname>Reik</surname><given-names>W</given-names></name><name><surname>Hawkins</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Beckwith-Wiedemann syndrome and assisted reproduction technology (ART</article-title><source>Journal of Medical Genetics</source><volume>40</volume><fpage>62</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1136/jmg.40.1.62</pub-id><pub-id pub-id-type="pmid">12525545</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markwald</surname><given-names>RR</given-names></name><name><surname>Fitzharris</surname><given-names>TP</given-names></name><name><surname>Manasek</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="1977">1977</year><article-title>Structural development of endocardial cushions</article-title><source>The American Journal of Anatomy</source><volume>148</volume><fpage>85</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1002/aja.1001480108</pub-id><pub-id pub-id-type="pmid">842477</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matouk</surname><given-names>IJ</given-names></name><name><surname>Raveh</surname><given-names>E</given-names></name><name><surname>Abu-lail</surname><given-names>R</given-names></name><name><surname>Mezan</surname><given-names>S</given-names></name><name><surname>Gilon</surname><given-names>M</given-names></name><name><surname>Gershtain</surname><given-names>E</given-names></name><name><surname>Birman</surname><given-names>T</given-names></name><name><surname>Gallula</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>T</given-names></name><name><surname>Barkali</surname><given-names>M</given-names></name><name><surname>Richler</surname><given-names>C</given-names></name><name><surname>Fellig</surname><given-names>Y</given-names></name><name><surname>Sorin</surname><given-names>V</given-names></name><name><surname>Hubert</surname><given-names>A</given-names></name><name><surname>Hochberg</surname><given-names>A</given-names></name><name><surname>Czerniak</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Oncofetal H19 RNA promotes tumor metastasis</article-title><source>Biochimica et Biophysica Acta</source><volume>1843</volume><fpage>1414</fpage><lpage>1426</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.03.023</pub-id><pub-id pub-id-type="pmid">24703882</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matouk</surname><given-names>IJ</given-names></name><name><surname>Halle</surname><given-names>D</given-names></name><name><surname>Raveh</surname><given-names>E</given-names></name><name><surname>Gilon</surname><given-names>M</given-names></name><name><surname>Sorin</surname><given-names>V</given-names></name><name><surname>Hochberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The role of the oncofetal H19 LNCRNA in tumor metastasis: Orchestrating the EMT-MET decision</article-title><source>Oncotarget</source><volume>7</volume><fpage>3748</fpage><lpage>3765</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6387</pub-id><pub-id pub-id-type="pmid">26623562</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMullen</surname><given-names>JR</given-names></name><name><surname>Jennings</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Differences between pathological and physiological cardiac hypertrophy: Novel therapeutic strategies to treat heart failure</article-title><source>Clinical and Experimental Pharmacology &amp; Physiology</source><volume>34</volume><fpage>255</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1681.2007.04585.x</pub-id><pub-id pub-id-type="pmid">17324134</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Basak</surname><given-names>T</given-names></name><name><surname>Datta</surname><given-names>K</given-names></name><name><surname>Naskar</surname><given-names>S</given-names></name><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of α-Crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction</article-title><source>Cell Death &amp; Disease</source><volume>4</volume><elocation-id>e582</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.114</pub-id><pub-id pub-id-type="pmid">23559016</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murrell</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Setting up and maintaining differential insulators and boundaries for genomic imprinting</article-title><source>Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire</source><volume>89</volume><fpage>469</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1139/o11-043</pub-id><pub-id pub-id-type="pmid">21936680</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mussa</surname><given-names>A</given-names></name><name><surname>Molinatto</surname><given-names>C</given-names></name><name><surname>Cerrato</surname><given-names>F</given-names></name><name><surname>Palumbo</surname><given-names>O</given-names></name><name><surname>Carella</surname><given-names>M</given-names></name><name><surname>Baldassarre</surname><given-names>G</given-names></name><name><surname>Carli</surname><given-names>D</given-names></name><name><surname>Peris</surname><given-names>C</given-names></name><name><surname>Riccio</surname><given-names>A</given-names></name><name><surname>Ferrero</surname><given-names>GB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Assisted reproductive techniques and risk of Beckwith-wiedemann syndrome</article-title><source>Pediatrics</source><volume>140</volume><elocation-id>4311</elocation-id><pub-id pub-id-type="doi">10.1542/peds.2016-4311</pub-id><pub-id pub-id-type="pmid">28634246</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odom</surname><given-names>LN</given-names></name><name><surname>Segars</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Imprinting disorders and assisted reproductive technology</article-title><source>Current Opinion in Endocrinology, Diabetes, and Obesity</source><volume>17</volume><fpage>517</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1097/MED.0b013e32834040a3</pub-id><pub-id pub-id-type="pmid">20962636</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KS</given-names></name><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Rahat</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Loss of imprinting mutations define both distinct and overlapping roles for misexpression of igf2 and of h19 lncrna</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>12766</fpage><lpage>12779</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx896</pub-id><pub-id pub-id-type="pmid">29244185</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>T-T</given-names></name><name><surname>Wang</surname><given-names>K-L</given-names></name><name><surname>Xiao</surname><given-names>G-Q</given-names></name><name><surname>Wang</surname><given-names>J-H</given-names></name><name><surname>Zhao</surname><given-names>H-D</given-names></name><name><surname>Kang</surname><given-names>Z-J</given-names></name><name><surname>Fan</surname><given-names>W-J</given-names></name><name><surname>Zhu</surname><given-names>L-L</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Cui</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>F-M</given-names></name><name><surname>Wang</surname><given-names>H-J</given-names></name><name><surname>Lam</surname><given-names>EW-F</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>H19/let-7/lin28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance</article-title><source>Cell Death &amp; Disease</source><volume>8</volume><elocation-id>e2569</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.438</pub-id><pub-id pub-id-type="pmid">28102845</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The role of genomic imprinting in biology and disease: An expanding view</article-title><source>Nature Reviews. Genetics</source><volume>15</volume><fpage>517</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/nrg3766</pub-id><pub-id pub-id-type="pmid">24958438</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piera-Velazquez</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Jimenez</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Role of endothelial-mesenchymal transition (endomt) in the pathogenesis of fibrotic disorders</article-title><source>The American Journal of Pathology</source><volume>179</volume><fpage>1074</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.06.001</pub-id><pub-id pub-id-type="pmid">21763673</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raveh</surname><given-names>E</given-names></name><name><surname>Matouk</surname><given-names>IJ</given-names></name><name><surname>Gilon</surname><given-names>M</given-names></name><name><surname>Hochberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The h19 long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory</article-title><source>Molecular Cancer</source><volume>14</volume><elocation-id>184</elocation-id><pub-id pub-id-type="doi">10.1186/s12943-015-0458-2</pub-id><pub-id pub-id-type="pmid">26536864</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>CA</given-names></name><name><surname>Boyle</surname><given-names>MH</given-names></name><name><surname>Burggraf</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="1989">1989</year><article-title>Reversible obstructive hypertrophic cardiomyopathy in the Beckwith-wiedemann syndrome</article-title><source>Pediatric Cardiology</source><volume>10</volume><fpage>225</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1007/BF02083298</pub-id><pub-id pub-id-type="pmid">2531862</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satgé</surname><given-names>D</given-names></name><name><surname>Vidalo</surname><given-names>E</given-names></name><name><surname>Desfarges</surname><given-names>F</given-names></name><name><surname>de Geeter</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A third case of cardiac neoplasm in a fetus with Beckwith-wiedemann syndrome: Epicardial angiofibroma</article-title><source>Fetal Diagnosis and Therapy</source><volume>20</volume><fpage>44</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1159/000081368</pub-id><pub-id pub-id-type="pmid">15608459</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sciarretta</surname><given-names>S</given-names></name><name><surname>Volpe</surname><given-names>M</given-names></name><name><surname>Sadoshima</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mammalian target of rapamycin signaling in cardiac physiology and disease</article-title><source>Circulation Research</source><volume>114</volume><fpage>549</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302022</pub-id><pub-id pub-id-type="pmid">24481845</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Gan</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Darehzereshki</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Kumar</surname><given-names>SR</given-names></name><name><surname>Lien</surname><given-names>CL</given-names></name><name><surname>Patterson</surname><given-names>M</given-names></name><name><surname>Tao</surname><given-names>G</given-names></name><name><surname>Sucov</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mononuclear diploid cardiomyocytes support neonatal mouse heart regeneration in response to paracrine igf2 signaling</article-title><source>eLife</source><volume>9</volume><elocation-id>e53071</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.53071</pub-id><pub-id pub-id-type="pmid">32167474</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>I</given-names></name><name><surname>Minamino</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Physiological and pathological cardiac hypertrophy</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>97</volume><fpage>245</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2016.06.001</pub-id><pub-id pub-id-type="pmid">27262674</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Hsieh</surname><given-names>S</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Williams-Simons</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>SP</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>H19 and igf2 monoallelic expression is regulated in two distinct ways by a shared cis acting regulatory region upstream of H19</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>1186</fpage><lpage>1195</lpage></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>M</given-names></name><name><surname>Frolova</surname><given-names>E</given-names></name><name><surname>Rottinghaus</surname><given-names>B</given-names></name><name><surname>Boe</surname><given-names>SP</given-names></name><name><surname>Grinberg</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Love</surname><given-names>PE</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Imprint control element-mediated secondary methylation imprints at the IGF2/H19 locus</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>5977</fpage><lpage>5983</lpage><pub-id pub-id-type="doi">10.1074/jbc.M208437200</pub-id><pub-id pub-id-type="pmid">12270940</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exosomal MIRNA let-7 from menstrual blood-derived endometrial stem cells alleviates pulmonary fibrosis through regulating mitochondrial dna damage</article-title><source>Oxidative Medicine and Cellular Longevity</source><volume>2019</volume><elocation-id>4506303</elocation-id><pub-id pub-id-type="doi">10.1155/2019/4506303</pub-id><pub-id pub-id-type="pmid">31949877</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tenorio</surname><given-names>J</given-names></name><name><surname>Romanelli</surname><given-names>V</given-names></name><name><surname>Martin-Trujillo</surname><given-names>A</given-names></name><name><surname>Fernández</surname><given-names>GM</given-names></name><name><surname>Segovia</surname><given-names>M</given-names></name><name><surname>Perandones</surname><given-names>C</given-names></name><name><surname>Pérez Jurado</surname><given-names>LA</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Fraga</surname><given-names>M</given-names></name><name><surname>Arias</surname><given-names>P</given-names></name><name><surname>Gordo</surname><given-names>G</given-names></name><name><surname>Dapía</surname><given-names>I</given-names></name><name><surname>Mena</surname><given-names>R</given-names></name><name><surname>Palomares</surname><given-names>M</given-names></name><name><surname>Pérez de Nanclares</surname><given-names>G</given-names></name><name><surname>Nevado</surname><given-names>J</given-names></name><name><surname>García-Miñaur</surname><given-names>S</given-names></name><name><surname>Santos-Simarro</surname><given-names>F</given-names></name><name><surname>Martinez-Glez</surname><given-names>V</given-names></name><name><surname>Vallespín</surname><given-names>E</given-names></name><collab>SOGRI Consortium</collab><name><surname>Monk</surname><given-names>D</given-names></name><name><surname>Lapunzina</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clinical and molecular analyses of Beckwith-wiedemann syndrome: Comparison between spontaneous conception and assisted reproduction techniques</article-title><source>American Journal of Medical Genetics. Part A</source><volume>170</volume><fpage>2740</fpage><lpage>2749</lpage><pub-id pub-id-type="doi">10.1002/ajmg.a.37852</pub-id><pub-id pub-id-type="pmid">27480579</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorvaldsen</surname><given-names>JL</given-names></name><name><surname>Duran</surname><given-names>KL</given-names></name><name><surname>Bartolomei</surname><given-names>MS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and igf2</article-title><source>Genes &amp; Development</source><volume>12</volume><fpage>3693</fpage><lpage>3702</lpage><pub-id pub-id-type="doi">10.1101/gad.12.23.3693</pub-id><pub-id pub-id-type="pmid">9851976</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakili</surname><given-names>BA</given-names></name><name><surname>Okin</surname><given-names>PM</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Prognostic implications of left ventricular hypertrophy</article-title><source>American Heart Journal</source><volume>141</volume><fpage>334</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1067/mhj.2001.113218</pub-id><pub-id pub-id-type="pmid">11231428</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Empel</surname><given-names>VPM</given-names></name><name><surname>Bertrand</surname><given-names>ATA</given-names></name><name><surname>Hofstra</surname><given-names>L</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name><name><surname>Doevendans</surname><given-names>PA</given-names></name><name><surname>De Windt</surname><given-names>LJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Myocyte apoptosis in heart failure</article-title><source>Cardiovascular Research</source><volume>67</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.cardiores.2005.04.012</pub-id><pub-id pub-id-type="pmid">15896727</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voellenkle</surname><given-names>C</given-names></name><name><surname>Garcia-Manteiga</surname><given-names>JM</given-names></name><name><surname>Pedrotti</surname><given-names>S</given-names></name><name><surname>Perfetti</surname><given-names>A</given-names></name><name><surname>De Toma</surname><given-names>I</given-names></name><name><surname>Da Silva</surname><given-names>D</given-names></name><name><surname>Maimone</surname><given-names>B</given-names></name><name><surname>Greco</surname><given-names>S</given-names></name><name><surname>Fasanaro</surname><given-names>P</given-names></name><name><surname>Creo</surname><given-names>P</given-names></name><name><surname>Zaccagnini</surname><given-names>G</given-names></name><name><surname>Gaetano</surname><given-names>C</given-names></name><name><surname>Martelli</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Implication of long noncoding rnas in the endothelial cell response to hypoxia revealed by RNA-sequencing</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>24141</elocation-id><pub-id pub-id-type="doi">10.1038/srep24141</pub-id><pub-id pub-id-type="pmid">27063004</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagenseil</surname><given-names>JE</given-names></name><name><surname>Nerurkar</surname><given-names>NL</given-names></name><name><surname>Knutsen</surname><given-names>RH</given-names></name><name><surname>Okamoto</surname><given-names>RJ</given-names></name><name><surname>Li</surname><given-names>DY</given-names></name><name><surname>Mecham</surname><given-names>RP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Effects of elastin haploinsufficiency on the mechanical behavior of mouse arteries</article-title><source>American Journal of Physiology. Heart and Circulatory Physiology</source><volume>289</volume><fpage>H1209</fpage><lpage>H1217</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00046.2005</pub-id><pub-id pub-id-type="pmid">15863465</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>HX</given-names></name><name><surname>Li</surname><given-names>YL</given-names></name><name><surname>Zhang</surname><given-names>CC</given-names></name><name><surname>Zhou</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>YL</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Microrna Let-7i negatively regulates cardiac inflammation and fibrosis</article-title><source>Hypertension</source><volume>66</volume><fpage>776</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.115.05548</pub-id><pub-id pub-id-type="pmid">26259595</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Gan</surname><given-names>P</given-names></name><name><surname>Cavallero</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>SR</given-names></name><name><surname>Lien</surname><given-names>CL</given-names></name><name><surname>Sucov</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Differential roles of insulin like growth factor 1 receptor and insulin receptor during embryonic heart development</article-title><source>BMC Developmental Biology</source><volume>19</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/s12861-019-0186-8</pub-id><pub-id pub-id-type="pmid">30909860</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weksberg</surname><given-names>R</given-names></name><name><surname>Shuman</surname><given-names>C</given-names></name><name><surname>Beckwith</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Beckwith-wiedemann syndrome</article-title><source>European Journal of Human Genetics</source><volume>18</volume><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2009.106</pub-id><pub-id pub-id-type="pmid">19550435</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>12</volume><fpage>2506</fpage><lpage>2515</lpage></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Bi</surname><given-names>J</given-names></name><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Zhi</surname><given-names>K</given-names></name><name><surname>Hua</surname><given-names>J</given-names></name><name><surname>Fang</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Up-regulated long non-coding RNA h19 contributes to proliferation of gastric cancer cells</article-title><source>The FEBS Journal</source><volume>279</volume><fpage>3159</fpage><lpage>3165</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08694.x</pub-id><pub-id pub-id-type="pmid">22776265</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>YS</given-names></name><name><surname>Jeong</surname><given-names>S</given-names></name><name><surname>Rong</surname><given-names>Q</given-names></name><name><surname>Park</surname><given-names>KY</given-names></name><name><surname>Chung</surname><given-names>JH</given-names></name><name><surname>Pfeifer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Analysis of the H19ICR insulator</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>3499</fpage><lpage>3510</lpage><pub-id pub-id-type="doi">10.1128/MCB.02170-06</pub-id><pub-id pub-id-type="pmid">17339341</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeisberg</surname><given-names>EM</given-names></name><name><surname>Tarnavski</surname><given-names>O</given-names></name><name><surname>Zeisberg</surname><given-names>M</given-names></name><name><surname>Dorfman</surname><given-names>AL</given-names></name><name><surname>McMullen</surname><given-names>JR</given-names></name><name><surname>Gustafsson</surname><given-names>E</given-names></name><name><surname>Chandraker</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name><name><surname>Roberts</surname><given-names>AB</given-names></name><name><surname>Neilson</surname><given-names>EG</given-names></name><name><surname>Sayegh</surname><given-names>MH</given-names></name><name><surname>Izumo</surname><given-names>S</given-names></name><name><surname>Kalluri</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Endothelial-to-mesenchymal transition contributes to cardiac fibrosis</article-title><source>Nature Medicine</source><volume>13</volume><fpage>952</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1038/nm1613</pub-id><pub-id pub-id-type="pmid">17660828</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>ASL</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>To</surname><given-names>KF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The interplay of Lncrna-h19 and its binding partners in physiological process and gastric carcinogenesis</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><elocation-id>450</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18020450</pub-id><pub-id pub-id-type="pmid">28230721</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LNCRNA H19 promotes epithelial-mesenchymal transition (EMT) by targeting mir-484 in human lung cancer cells</article-title><source>Journal of Cellular Biochemistry</source><volume>119</volume><fpage>4447</fpage><lpage>4457</lpage><pub-id pub-id-type="doi">10.1002/jcb.26537</pub-id><pub-id pub-id-type="pmid">29219208</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>H19 potentiates let-7 family expression through reducing PTBP1 binding to their precursors in cholestasis</article-title><source>Cell Death &amp; Disease</source><volume>10</volume><elocation-id>168</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-019-1423-6</pub-id><pub-id pub-id-type="pmid">30778047</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>T</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Men</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Giang</surname><given-names>K</given-names></name><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Carmichael</surname><given-names>GG</given-names></name><name><surname>Taylor</surname><given-names>HS</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>10221</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10221</pub-id><pub-id pub-id-type="pmid">26687445</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Si</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Bartolomei</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Combined Single-Cell Profiling of lncRNAs and Functional Screening Reveals that H19 Is Pivotal for Embryonic Hematopoietic Stem Cell Development</article-title><source>Cell Stem Cell</source><volume>24</volume><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2018.11.023</pub-id><pub-id pub-id-type="pmid">30639035</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67250.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Prosser</surname><given-names>Benjamin L</given-names></name><role>Reviewing Editor</role><aff><institution>University of Pennsylvania Perelman School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Prosser</surname><given-names>Benjamin L</given-names></name><role>Reviewer</role><aff><institution>University of Pennsylvania Perelman School of Medicine</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.02.23.432554">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.02.23.432554v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Park et al., utilize highly tractable mouse models to interrogate a particular class of genetic lesions observed in the imprinting disorder and overgrowth syndrome, Beckwith-Wiedemann syndrome (BWS). Because more than one gene is abnormally expressed in BWS, which is caused by loss of imprinting at the H19/IGF2 locus, the authors vary the expression of both genes to investigate the source of cardiovascular phenotypes in BWS. They are able to ascribe independent cardiac phenotypes that result from IGF2 overexpression and H19 loss of expression, and provide mechanistic insight into how the altered expression of each gene contributes to cardiac dysfunction.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Cardiac pathologies in mouse loss of imprinting models are due to misexpression of H19 long noncoding RNA&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Benjamin L Prosser as Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Edward Morrisey as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential Revisions (for the authors):</p><p>1) Per the reviewer comments below, additional data is needed regarding H19 and IGF2 levels in the various models utilized, as well as validation of disruption of let7-H19 interaction or let7 levels.</p><p>2) Representative gels and images should not be relied upon for conclusive statements – please provide transparent quantification for all major observations.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Some measure of organ level hypertrophy at P1 and 2 months should be shown for LOI (and LOI+H19 BAC hearts, where appropriate).</p><p>2. In general, the cardiomegaly/hypertrophy data is not presented clearly throughout the manuscript a graph demonstrating HW/TL measurements across all genotypes at similar ages would greatly simplify and strengthen this presentation.</p><p>3. One particularly weakly supported conclusion is that LOI leads to elevated levels of cyclins or p-AKT suggested from Figure 2D, which is very unclear from the representative image (particularly once normalized to t-AKT). Other specific examples include quantification of Ki-67 or cell surface area with the loss of H19 lncRNA, or that interstitial fibrosis is increased in the LOI animals.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. The authors measured serum IGF2 level as an indicator of the increased IGF2 level in LOI neonates. This is reasonable as the authors showed that the cardiac IGF2 is not cell-autonomous. As serum IGF2 is circulating, the cardiac expression pattern of InsR/Igf1r would be helpful to understand the exact target cell type of IGF2; are the IGF2 receptors expressed in a substantial way in endothelial cells, or cardiomyocytes?</p><p>2. In H19BAC mouse model, cardiac H19 expression data would be helpful to prove that the H19 expression is recovered to the wild-type level. Would the H19 expression from BAC transgene show the same pattern as the endogenous H19 expression throughout aging? Is it possible to perform H19 in situ staining on 6-month and later stages of H19BAC hearts as shown in Figure 5A?</p><p>3. In H19ΔEx1/H19+ mouse, was Igf2 expression affected? Previous mouse models with H19 deletions showed increased Igf2 expression in certain tissues. Figure 2B mentions that Igf2 is monoallelic in H19ΔEx1/H19+ neonate heart. Although it's less likely for IGF2 signaling to be altered here as cardiomegaly was not observed, it might worth confirming that the serum IGF2 level in H19ΔEx1/H19+ neonates is unchanged as the cardiac IGF2 is not cell-autonomous.</p><p>4. In line 239-240; are the heart weight/tibia length ratio values normalized to the WT littermates? According to the line 127, the value from 6-month WT mice is lower than the value from the LOI+BAC transgene mice. This doesn't match with the text in line 238-239 (&quot;hearts from 6-month LOI mice carrying the H19 transgene are not enlarged as determined by heart weight/tibia length ratios&quot;). Also in line 340-342 (&quot;Adult H19ΔLet7/H19+mice displayed cardiomegaly as measured by increased heart weight/tibia length ratios&quot;), the stage of the mice when these values were measured is missing (this wild-type value is much lower than the aforementioned 6-month wild-type value).</p><p>5. In H19ΔLet7/+ mouse, was let7 level measured in heart? If H19 functions through regulating let7 stability, it's important to confirm that let7 expression is altered in these mutants.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67250.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential Revisions (for the authors):</p><p>1) Per the reviewer comments below, additional data is needed regarding H19 and IGF2 levels in the various models utilized, as well as validation of disruption of let7-H19 interaction or let7 levels.</p></disp-quote><p>Expression data for our 4 mouse models are fully documented:</p><p>LOI vs WT: see Figure 1C, D, E.</p><p>LOI vs LOI+H19: see Figure 2—figure supplement 2.</p><p>H19ΔEx1 vs WT: see Figure 2—figure supplement 3.</p><p>H19Δlet7 vs WT: see Figure 6 and Figure 6—figure supplement 1.</p><p>We have validated disruption of let7-H19 interactions in the H19Δlet7 model. This is described in the main text (Lines 329-33) and in Figure 6—figure supplement 6. Briefly, we used biotinylated oligonucleotides to “pull-down” H19 lncRNA and show that let-7 miRNA copurifies with wild type H19 lncRNA but not with H19Δlet7 lncRNA. Methods for this are described on lines 579-592.</p><disp-quote content-type="editor-comment"><p>2) Representative gels and images should not be relied upon for conclusive statements – please provide transparent quantification for all major observations.</p></disp-quote><p>The data from all western blots were quantified using Image J software and presented in Figure 2—figure supplement 1, Figure 3—figure supplement 1, and Figure 4—figure supplement 1, and Figure 6—figure supplement 2. As described in the figure legends, these supplemental figures describe quantitation of the representative blots displayed in the main figures combined with quantitation of additional blots that assayed independent biological replicates.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Some measure of organ level hypertrophy at P1 and 2 months should be shown for LOI (and LOI+H19 BAC hearts, where appropriate).</p></disp-quote><p>Heart weight/tibia length data for 2 months are presented on 116-117.</p><disp-quote content-type="editor-comment"><p>2. In general, the cardiomegaly/hypertrophy data is not presented clearly throughout the manuscript a graph demonstrating HW/TL measurements across all genotypes at similar ages would greatly simplify and strengthen this presentation.</p></disp-quote><p>Please see above for full details. Based on the differences between different mouse models and their genetic background it would not be appropriate to compare across different data sets. To overcome this issue our study compares each mouse model with wild type littermates.</p><disp-quote content-type="editor-comment"><p>3. One particularly weakly supported conclusion is that LOI leads to elevated levels of cyclins or p-AKT suggested from Figure 2D, which is very unclear from the representative image (particularly once normalized to t-AKT). Other specific examples include quantification of Ki-67 or cell surface area with the loss of H19 lncRNA, or that interstitial fibrosis is increased in the LOI animals.</p></disp-quote><p>Data from experiments described in Figure 2 are quantitated and displayed in Figure 2—figure supplement. We used Image J to quantitate the data from the representative blot displayed in Figure 2D and from 2 other independent blots analyzing independent biological samples. We calculated that p-AKT and p-S6K1 increase by 1.9-fold (p = 0.01) and by 6.7-fold (p&lt;0.001). respectively.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. The authors measured serum IGF2 level as an indicator of the increased IGF2 level in LOI neonates. This is reasonable as the authors showed that the cardiac IGF2 is not cell-autonomous. As serum IGF2 is circulating, the cardiac expression pattern of InsR/Igf1r would be helpful to understand the exact target cell type of IGF2; are the IGF2 receptors expressed in a substantial way in endothelial cells, or cardiomyocytes?</p></disp-quote><p>Igf1R and InsR kinase genes are each expressed in both cardiomyocytes and in cardiac endothelial cells at comparable levels. (To provide some context: in our RNA-seq data sets, counts are about 8-fold less than for GAPDH).</p><p>The importance of IGF signaling through Insr/Igf1R in cardiomyocytes and in neonatal heart development is well documented and we have added several references to the main text (Wang 2019, Li 2011, Geng 2017, Shen 2020). In fact, Shen 2020 describes the importance of IGF2 synthesized by endothelial cells in regulating embryonic cardiomyocytes which may be quite relevant in our system.</p><p>The biological functions of IGF signaling in endothelial cells are less well characterized (especially in regard to early development) but ECs clearly respond to IGF stimulation and studies of embryonic stem cells indicate that IGF signaling regulates vascular development.</p><p>Our studies show cell non-autonomous effects of LOI on cardiomyocytes but do not rule out the possibility that the 2X Igf2 dosage also impacts endothelial cells. We edited the discussion to make this point clear.</p><p>Thank you for this comment. We think the main text is significantly clearer now that we made these points explicit.</p><disp-quote content-type="editor-comment"><p>2. In H19BAC mouse model, cardiac H19 expression data would be helpful to prove that the H19 expression is recovered to the wild-type level. Would the H19 expression from BAC transgene show the same pattern as the endogenous H19 expression throughout aging? Is it possible to perform H19 in situ staining on 6-month and later stages of H19BAC hearts as shown in Figure 5A?</p></disp-quote><p>H19 and Igf2 expression data for H19 BAC mice are now included in Figure 2—figure supplement 2. In addition, we cite Kaffer et al., (PMID 10921905) that describes expression analyses of the BAC mice using in situ hybridization.</p><p>The patterns for expression of H19 in adult animals and their changes in regard to environmental stresses are part of an ongoing study.</p><disp-quote content-type="editor-comment"><p>3. In H19ΔEx1/H19+ mouse, was Igf2 expression affected? Previous mouse models with H19 deletions showed increased Igf2 expression in certain tissues. Figure 2B mentions that Igf2 is monoallelic in H19ΔEx1/H19+ neonate heart. Although it's less likely for IGF2 signaling to be altered here as cardiomegaly was not observed, it might worth confirming that the serum IGF2 level in H19ΔEx1/H19+ neonates is unchanged as the cardiac IGF2 is not cell-autonomous.</p></disp-quote><p>The reviewer brings up an interesting and important point. It is a longstanding complication for all groups analyzing H19 phenotypes that H19 deletion typically results in increased levels of Igf2. Consistent with these previous findings, H19DEx1/+ mice show levels of Igf2 mRNA that are typically 10% higher than their wild type littermates. For this reason, we were very excited to see that Igf2 is not altered in H19Dlet7/H19Dlet7 mice. This means that phenotypes in this model can be definitively assigned to changes in H19 and we can conclude that cardiomyopathy is not dependent on increased Igf2. We have modified Figure 6 to include information about Igf2 expression in H19Dlet7/H19Dlet7 mice and underline the importance of this result in the Figure 6 legend (lines 721-722).</p><disp-quote content-type="editor-comment"><p>4. In line 239-240; are the heart weight/tibia length ratio values normalized to the WT littermates? According to the line 127, the value from 6-month WT mice is lower than the value from the LOI+BAC transgene mice. This doesn't match with the text in line 238-239 (&quot;hearts from 6-month LOI mice carrying the H19 transgene are not enlarged as determined by heart weight/tibia length ratios&quot;). Also in line 340-342 (&quot;Adult H19ΔLet7/H19+mice displayed cardiomegaly as measured by increased heart weight/tibia length ratios&quot;), the stage of the mice when these values were measured is missing (this wild-type value is much lower than the aforementioned 6-month wild-type value).</p></disp-quote><p>We address this point in detail above. Based on the differences between genetic backgrounds, it would not be appropriate to compare between different data sets. Our study was designed so that each model is compared always to wild type littermates. Essentially, our paper describes 4 independent studies: WT vs LOI, LOI+BAC vs LOI, WT vs H19DEx1/+, and WT vs H19Dlet7/H19Dlet7. We consider it a strength of our study that we consistently account for potential strain effects and that we demonstrate H19 function in 4 completely independent comparisons.</p><p>However, we also understand the reviewer’s confusion and modified the main text to make clear that each model is being compared to its wild type littermates only.</p><disp-quote content-type="editor-comment"><p>5. In H19ΔLet7/+ mouse, was let7 level measured in heart? If H19 functions through regulating let7 stability, it's important to confirm that let7 expression is altered in these mutants.</p></disp-quote><p>The deletion of the let7 binding site on H19 was made with the intent to alter H19-let7 physical interactions. The model is successful as confirmed in Figure 6—figure supplement 1. In Figure 6—figure supplement 1, we also show that steady-state let7 miRNA levels are equivalent to those seen in wild type mice. Thus our conclusion is that the mutation is likely to affect let7 bioavailability. Consistent with this hypothesis, we see altered expression of several well characterized let7 target genes including Hmga2 and lpl.</p></body></sub-article></article>